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As obligate intracellular parasites, viruses must infect a host-cell and requisition cellular
machinery for viral replication. JC polyomavirus (JCPyV) is a ubiquitous human pathogen that can cause
a lytic infection in glial cells of the central nervous system in immunocompromised individuals. In order
to initiate infection however, the virus must alter prototypical cellular processes that promote cellular
homeostasis. The main driver of these processes are signaling pathways, the means by which the cell
interacts and responds to the extracellular environment. Many signaling cascades are responsible for
promoting growth, responding to pathogens, initiating differentiation, or inducing cell death. Through
the works described herein, I have discovered that JCPyV utilizes the mitogen-activated protein kinase,
extracellular signal-regulated kinase (MAPK-ERK) cascade, to facilitate infection.
These works sought to characterize how JCPyV, the etiological agent of the fatal
neurodegenerative disease progressive multifocal leukoencephalopathy (PML), usurps MAPK-ERK
signaling to promote infectious processes. Prior to these works, little was known about JCPyV
manipulation of cellular signaling cascades. Our work has demonstrated that each of the core kinases
that comprise the MAPK-ERK pathway: Raf, MEK, and ERK, are required for successful JCPyV infection.
The terminal protein of this cascade, ERK, can activate hundreds of cellular substrates including

transcription factors (TFs) upon phosphorylation under normal conditions. During viral challenge, JCPyV
induces the activation of ERK signaling during the early stages of infection, but only requires ERK for
facilitating viral gene transcription, which occurs during later stages of viral infection. Viral genomic
replication processes such as: nuclear accumulation of TFs, viral promoter activity, and the transcription
of viral early genes and production of viral early proteins, all require MAPK-ERK activity, demonstrating
the critical role the MAPK-ERK pathway plays during JCPyV infection.
Overall, these works demonstrate that JCPyV, like many DNA viruses, utilizes the MAPK-ERK
pathway to dysregulate the host-cell and promote infection. As protein kinases are a new and emerging
population of drug targets, characterizing how JCPyV manipulates the MAPK-ERK pathway may identify
potential anti-viral therapeutics. Together, these findings have defined how JCPyV activation of the
MAPK-ERK cascade specifically upregulates downstream effectors to promote viral infection.
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CHAPTER 1
INTRODUCTION
This chapter contains a modified form of the published work from: DuShane, J.K.; Maginnis, M.S. Human
DNA Virus Exploitation of the MAPK-ERK Cascade. Int. J. Mol. Sci. 2019, 20, 3427. Reproduction of the
published work for thesis is permitted by the publisher Multidisciplinary Digital Publishing Institute.
1.1. Host-Pathogen Interactions and Microbial Disease
Microorganisms like bacteria, fungi, and viruses make up the most abundant forms of biological
entities on the planet, totaling an estimated one trillion different species [1]. To put this into context,
there are nearly 1013 cells within the human body, outnumbered by the 1014 bacterial and fungal cells
present in our bodies [2], microbes that are further outnumbered by viruses by over tenfold [3]. These
various types of microbes are often considered in the context of how they impact human health,
specifically which are pathogenic microbes that can pose a threat or cause damage to its host. The
interaction between pathogen and host is at the crux how human health is influenced; both the invading
organism and host defenses play roles in determining the outcome of this interaction.
Humans play host to an incredible number and diverse population of microorganisms. Colonizing
nearly every surface of the human host, many of these microbes live in symbiosis with humans, helping
us to take in vital nutrients, develop functioning immune systems, and even reproduce [4]. However,
these oft commensal microbes must remain in balance and typically restricted to particular areas within
the host environment. Under conditions of normal flora growing unchecked or unchallenged, the host
can develop a disease state that can range from asymptomatic to catastrophic. The pathogenesis of
microbial organisms can often lead to the onset of disease, which originates at the point of direct
interaction between microbe and host-cell at the molecular level.
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1.2. Viral Pathogens
Distinct from bacteria and fungi, viral pathogens are another classification of microorganisms that
play major roles in the development of human diseases. Viruses by definition are infectious obligate,
intracellular parasites comprised of genetic material, a proteinaceous capsid and sometimes a lipid
envelope [5]. These obligate parasites can only replicate within a host and require the requisition of
replication machineries like host-cell ribosomes, in order to generate new viral progeny [5]. While
seemingly simple in composition, viruses are exceedingly complex and highly evolved genomic delivery
systems. Viruses are typically genetically conservative, encoding only enough information to allow for
manipulation of host-cell replication processes to facilitate a successful infection.
For nearly all mammalian viruses, successful infection is predicated upon the host-cell being
susceptible (endowed with mechanisms that facilitate the initiation of infection) and permissive
(allowing for viral replication), factors that both define cellular tropism and the diseases associated with
infection of these tissues [5]. However, not all viral infections result in the onset of a disease state; some
viruses can remain dormant and undetected within the host-cell. Viral pathogens can exist in stages of
active replication (lytic) or in non-replicating states (non-lytic), with the former often associated with the
onset of human disease. Some viruses, can also establish permanent infections within the host that
persist for the duration of the host’s lifetime, denoted as a persistent infection. A persistent infection
can range from a non-productive infection to integration into the host genome to even continuous lowlevels of viral replication [6]. These infectious strategies can be employed by a virus in response to the
host-cell environment, in order to promote or induce the most suitable climate for viral survival.
1.3. JC polyomavirus
1.3.1. Characteristics of JCPyV
The human JC polyomavirus (JCPyV), is a member of the Polyomaviridae family of viruses, which is
divided into the four genera alpha-, beta-, delta- and gammapolyomavirus containing more than 80 viral
2

species [7]. JCPyV is a member of the betapolyomavirus, which includes other human polyomaviruses
and the type species simian virus 40 (SV40) polyomavirus [7]. JCPyV is a non-enveloped, doublestranded DNA virus with a capsid 40-45 nm in diameter [8]. This proteinaceous capsid is comprised of
three distinct structural viral proteins (VPx) 1, 2, and 3. The outermost portion of the capsid is made up
of 72 VP1 pentamers, that serve as the viral attachment protein for JCPyV. These VP1 pentamers from Cterminal disulfide bonds with neighboring pentamers, and interact with either a VP2 or VP3 molecule on
the interior surface, providing integrity to the capsid structure [9-11]. Housed within the capsid is the
circular, supercoiled DNA genome that is roughly 5,130 bp [12]. Encoded within the JCPyV genome are
seven viral proteins including: small t-antigen (tAg), large T-antigen (TAg), spliced variant t-antigens
(Tag), agnoprotein, VP1, VP2, and VP3 [13]. Like most DNA viruses, the JCPyV genome is bidirectional in
nature, with the viral early genes (t-antigens) separated from the viral late genes (VPx) by a non-coding
control region (NCCR) [14]. These distinct regions are transcribed in opposite directions beginning with
the early region, followed by a transition to late gene transcription and DNA replication. The
consequences of this lytic replication cycle has far reaching implications for infected individuals and in
rare instances can lead to the development of a fatal neurodegenerative disease known as progressive
multifocal leukoencephalopathy (PML).
1.3.2. Transmission and Tropism
The majority of evidence from seroepidemiology studies suggests that JCPyV infects approximately
50-80% of the human population [15,16]. In healthy individuals, JCPyV establishes an asymptomatic,
lifelong persistent infection in the kidney tissues after initial infection of the tonsillar tissues [17-20].
During this persistent infection of the kidney, low levels of viral DNA can be detected through shedding
of JCPyV into the urine of infected individuals [12].
While initial JCPyV infections can occur in the tonsillar tissues, detection of JCPyV DNA in the
saliva is exceedingly rare, signaling that the transmission of JCPyV virions to new hosts is likely
3

associated with exposure to contaminated urine [19-21]. The spread of JCPyV across hosts occurs
through human contact with the virus in the environment, often taken in through either the mouth or
nose to gain access to the bloodstream [21]. The viral strain most often found in the environment is
known as the archetype strain and is only associated with infection of healthy individuals. The virus
establishes a low level, persistent infection in the kidney resulting in viral shedding in the urine [17]. In
immunocompetent individuals, the virus will remain sequestered in the kidney tissues for the lifetime of
the individuals. However, during instances of severe immunosuppression, JCPyV can gain access to the
central nervous system (CNS) through hematogenous spread into the central nervous system
(CNS),where it targets astrocytes and oligodendrocytes, resulting in a lytic infection [22,23]. While the
mechanism utilized by the virus to gain access to the CNS is currently unknown, it has been suggested
that JCPyV infection of B cells, could facilitate the spread of JCPyV [24]. The lytic destruction of
oligodendrocytes leads to the demyelination of multifocal regions within the CNS. These demyelinated
regions spread rapidly and through multiple origin points within the CNS, demarking the development of
progressive multifocal leukoencephalopathy (PML).
1.4. Progressive Multifocal Leukoencephalopathy
1.4.1. Disease Pathology and Diagnosis
JCPyV infection was first identified as the etiological agent of PML in 1971 [25]. Progressive
multifocal leukoencephalopathy is a fatal neurodegenerative disease caused by the lytic infection of glial
cells within the CNS [22,23]. The demyelination of the white matter due to oligodendrocyte lysis leads to
the loss of neurons and the onset of PML-associated symptoms including loss of motor function,
cognitive impairments, and death [26]. PML diagnosis has traditionally been established through the
detection of viral DNA or proteins present in the cerebrospinal fluid (CSF) or in brain biopsy samples,
while confirmatory MRI scans are also employed to visualize the presence of PML lesions within brain
tissues (Figure 1.1) [27]. In general, the prognosis for individuals with PML is poor as there are currently
4

no treatments available that prevent or stop the progression of this disease. The therapies currently
utilized in these PML populations focus on reconstitution of the host immune system through various
treatments, each of which however, can lead to equally as devastating consequences as PML itself.

Figure 1.1. PML development.

MRI displaying PML lesion development in white matter of the brain. Adapted from [27] with permission
from Springer Nature. Arrows denote developing PML lesions.
1.4.2. Populations at Risk
To date, the majority of PML cases are associated with HIV-1+ status, the development of which is
often classified as an AIDS-defining illness. An estimated 80% of PML cases are associated with an HIV-1
infection, a rate significantly higher than in other immunosuppressed populations [28]. Despite the
advent of anti-retroviral therapies to help combat HIV-1 progression, AIDS-associated PML cases remain
linked to a 50% mortality rate [29,30]. Current treatment regimens for PML in HIV-1+ individuals centers
around the reconstitution of the immune system, through the implementation of highly active
antiretroviral therapies (HAART).
A new and emerging group of individuals increasingly at risk for the development of PML are
individuals suffering from immune-mediated disorders, whom are undergoing prolonged
immunomodulatory therapy treatments including those derived from monoclonal antibodies. One such
5

treatment, natalizumab, a treatment for relapsing-remitting multiple sclerosis (MS) and Crohn’s disease
[31]. Natalizumab is an IgG4 monoclonal antibody that binds to the 4 subunit of the very late antigen-4
integrin on leukocytes, preventing leukocyte migration to the brain [10]. This decrease in immune
surveillance in combination with JCPyV seropositivity elevates the risk of PML development, a risk that
increases to 1:500 cases after 24 months of continuous natalizumab treatment [31]. PML prevention in
these populations is complex; the implementation of antiretroviral treatments for HIV-1 infections or
immune restoration through the cessation of immunosuppressant treatment are often employed to
stop PML development or progression. These treatment courses however, can induce a potentially fatal
immune reconstitution inflammatory syndrome (IRIS), which causes an influx of immune mediators and
subsequent increased inflammatory response surrounding PML lesions [32]. The treatment options
surrounding these high-risk PML populations are severely restrictive and often result in patients making
difficult choices between risking PML development or suffering through the symptoms of their
immunosuppressed-state.
Individuals diagnosed with immune-mediated disorders now represent 3-5% of the population, a
number that is ever expanding [33]. While treatments like natalizumab are designed to ease symptoms
associated with these disorders, they often leave the patient vulnerable to secondary infections or viral
reactivation as is the case with JCPyV. Without an effective treatment for PML currently available,
elucidating the role of JCPyV infection in PML development is paramount for future isolation of
therapeutic drug targets.
1.5. JC polyomavirus Lifecycle
1.5.1. Viral Attachment, Entry, and Trafficking
JCPyV infection is initiated via attachment to 2,6-linked sialic acid on lactoseries
tetrasaccharide c (LSTc) through VP1, the major viral capsid protein [34-36]. Viral binding to LSTc also
involves interactions with the proximal GlcNAc residue, an interaction that is predominantly responsible
6

for binding specificity [12,34]. Interestingly, there are distinct VP1 residues that are key for binding to
LSTc: L54, N123, S266 and S268 [34] Interestingly, mutations in these specific residues are found in 90%
of JCPyV viral isolates from individuals with PML [37,38]. These PML-associated mutations in VP1 are not
found in JCPyV in urine samples, suggesting that VP1 mutations are critical for successful viral spread
from the kidney into the CNS. While it is currently unknown if the 2,6-linked sialic acid receptor is
expressed on a glycolipid or glycoprotein, the sialic acid receptor has been demonstrated to specifically
mediate viral attachment [34-36].
Like many other viruses, JCPyV requires a secondary receptor to promote infection, which in the
case of JCPyV is the serotonin 5-hydroxytryptamine 2 family of receptors (5-HT2R), subtypes A, B, and C,
which are required for viral entry [39-42]. Initial investigations into the role of these G protein-coupled
receptors in JCPyV infection utilized chlorpromazine and function-blocking antibodies that act as
antagonists of the serotonin receptor that resulted in significantly reduced infection rates [39,40],
suggesting that JCPyV may require the 5-HT2Rs during infection. Until recently, little was known about
the interaction between JCPyV and the 5-HT2Rs. It was unclear if JCPyV interactions with the 5-HT2Rs
were of a ligand-binding nature, or if the sheer proximity of the virus initiated the internalization of the
receptor into a signalosome. However, recent findings have identified that JCPyV directly and transiently
interacts with each of the 5-HT2R subtypes (A, B, and C), at 5 minutes post-viral challenge as determined
through proximity ligation assays [43]. These findings highlight the direct activation of the 5-HT2Rs and
implicate these receptors in downstream processes that may also be needed for successful viral
infection. However, additional findings have confirmed that JCPyV infection can proceed in a 5-HT2Rindependent manner, first identified in human brain microvascular endothelial cells (lack 5-HT2AR
expression) [44]. These findings highlight an alternative JCPyV infection mechanism in differing cell
types.
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Upon engagement with the serotonin receptor, JCPyV utilizes clathrin-mediated endocytosis
(CMS) and associated CME machineries including: dynamin, AP2, and -arrestin [42,45] for host-cell
entry. Internalized JCPyV virions were found to localize with clathrin during timepoints congruent with
JCPyV internalization, further characterizing the role of CME in JCPyV entry [42]. Once within the
clathrin-coated pit, JCPyV traffics through the endocytic compartment [46-48] by way of microtubules
and microfilaments [12,45,49]. JCPyV traffics through Rab5+ early endosomes then to caveolin-1+ late
endosomes [47] before eventually arriving at the endoplasmic reticulum (ER). After entrance into the
ER, JCPyV is thought to transverse the ER-membrane by capitalizing on the ER-associated degradation
pathway (ERAD) in order to gain access to the cytoplasm once more [12]. It is postulated that the viral
capsid undergoes partial disassembly during and after ER localization, as shedding of VP1 pentamers and
exposure of VP1 in the interior of the capsid indicates capsid destabilization as seen in other closely
related polyomaviruses [50,51]. While currently unknown for JCPyV, this capsid destabilization and
subsequent exposure of nuclear localization signals in other polyomaviruses facilitates the virion to gain
access to the nucleus for genomic deposition through the nuclear pore complex [52,53]. As a DNA virus,
the localization of JCPyV DNA into the nucleus is necessary for successful viral transcription and
translation and eventual formation of new viral progeny (Figure 1.2).
1.5.2. Viral Transcription and Replication
In cases of immunocompromised individuals that are JCPyV seropositive, the virus genome will
undergo mutations in the NCCR that result in the generation of a pathogenic form of the virus [18,54].
This neuroadaptation of JCPyV is thought to occur within infected B cells, which may act as the vehicle
that transports the reactivated virus from the kidney to the central nervous system (CNS) [55]. These
alterations to the NCCR are thought to play critical roles in the transcription and replication of the viral
genome in the context of the lytic infection associated with PML development. In general, the archetype
NCCR is made up of six blocks: a, b, c, d, e, and f [56]. However, in PML strains there is significant
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variations within and across the NCCR. In many PML strains, blocks b and d are no longer present,
representing a loss of repressor elements while blocks a, c, and e exist as tandem repeats leading to
duplication of enhancer elements. The deletion and repetition of these key regions create critical
transcription factor binding sites that may confer selective advantages for these PML strains within the
CNS [57].

Figure 1.2. JCPyV infectious lifecycle.
JCPyV (blue virion) engages the host cell via the 2,6-linked sialic acid on the exterior cell surface (1). Interactions
between JCPyV and the 5-HT2 serotonin receptor facilitates viral internalization via clathrin-mediated endocytosis
(2). The virus traffics through the endocytic compartment to the endoplasmic reticulum (ER). Interactions with ERassociated machineries likely induce the destabilization of the viral capsid (red virion) that promote nuclear
deposition (3). Upon nuclear translocation, viral transcription and replication are initiated, driving the production
of new viral genomes and capsids (4). These components will spontaneously assembly (5) and undergo egress (6)
from the infected cell through host-cell lysis. Created with BioRender.
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The JCPyV genome is bidirectional in nature, with the viral early genes (T-antigens) separated from
the viral late genes (VPx) by the NCCR [14]. The initiation of viral transcription occurs at the origin of
replication (ORI) within the NCCR. Expression of the early gene region occurs first, prior to DNA
replication, and proceeds counterclockwise from the NCCR [13]. This region is comprised of the Tantigen proteins, including largeT-antigen (TAg) and small T antigen (tAg). TAg is a key multifunctional
protein that plays critical roles in promoting JCPyV infection [58]. Upon the sufficient production of TAg
within the infected cell, TAg acts as a molecular switch, initiating transcription of the viral late genes and
viral DNA replication through direct interaction with the JCPyV ORI [12]. The T-antigens are crucial
proteins necessary for driving the host-cell into a proliferative state (S phase) in order to promote viral
replication. These vital viral proteins, are multifunctional proteins that can induce cell cycle progression
and prevent host-cell apoptosis, processes critical for productive viral infection. Less is currently
understood about the functions of the viral tAg protein. However, it has been reported that this protein
plays roles in host-cell cycle manipulation and DNA replication by interacting with both PP2A and Rb
[59,60], proteins that are critical to the regulation of the cell cycle. Through direct interaction with Rb,
members of the E2F family of transcription factors are able to dissociate and promote cell cycle
progression [59]. In this way, the production of these early viral t-antigens work to prime the cell for
viral replication through alterations in the cell phase.

10

Figure 1.3. JCPyV genome.
Viral early genes encoded within the JCPyV genome including the T-antigens (large, small and spliced variant) are
separated from the viral late genes which include agnoprotein and the viral capsid proteins (VP1, VP2 and VP3) by
the non-coding control region. Published in [61] under Creative Commons License.

In contrast, the viral late gene region is transcribed clockwise from the NCCR, on the opposing
strand of the viral genome. These genes encode for the capsid proteins VP1, VP2, and VP3 as well as the
agnoprotein, a protein postulated to act as a viroporin [62]. There are several host-cell transcription
factors identified that facilitate viral DNA replication including SP-1, NFI, Pur, YB-1, NFAT4, SMADs,
cMyc, and more [63-68]. Each of these transcription factors, and many more, play roles in facilitating
multiple processes of the viral lifecycle such as regulating the switch from early to late gene expression
(YB-1 and Pur) to increasing late gene production (NFAT4) [67,69]. Interestingly NFAT4, a transcription
factor necessary for both JCPyV and SV40 infection, has been shown to bind directly to the JCPyV
promoter to activate both early and late gene transcription [67,70]. Further, the requirement of this
transcription factor during JCPyV infection suggests that viral infection requires calcium signaling
activation to facilitate infection [67]. Moreover, JCPyV utilization of transcription factors including
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NFAT4, cMyc, and SMADs also suggests viral induction of a critical signaling pathway that governs the
activation of these particular factors, the mitogen-activated protein kinase cascade (MAPK) [71,72].
1.6. Cellular Signaling Pathways: Driver of Viral Infection
As obligate intracellular parasites, viruses require host cells for productive infection and replication.
While the specific host-cell mechanisms required for successful infection vary between virus types, the
induction or manipulation of host-cell signaling cascades is essential for successful viral infection and can
influence viral pathogenesis. One pathway known to be required by many different types of DNA and RNA
viruses is the extracellular signal-regulated kinase (ERK) cascade, a specific facet of the mitogen-activated
protein kinase pathway (MAPK-ERK). As a central regulator of cellular response to environmental stimuli,
the MAPK-ERK pathway predominantly transmits extracellular signals that induce cellular proliferation,
differentiation, and survival [71]. Both DNA and RNA viruses usurp the MAPK-ERK signaling pathway to
mediate multiple aspects of the virus infectious cycle [73-75]. DNA viruses alter MAPK-ERK signaling to
promote viral internalization, dysregulate the cell cycle, regulate viral replication, and prevent host-cell
death (Figure 1.4). The exploitation of these cellular processes are often aided by specific viral proteins
that dysregulate host-cell protein function and thereby alter cellular signaling outcomes to benefit viral
survival (Table 1.1). It is the differential utilization of this pathway by multiple DNA viruses that highlights
the dynamic nature of the MAPK-ERK pathway within the cell and the importance of its function in
regulating a wide variety of cellular fates that ultimately influence viral infection and the onset of human
disease.
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MAPK-ERK Role in Infectious Lifecycle
Viral Family

Virus
Enhances Viral
Replication

Adenoviridae

HAdV

+
(E4-ORF1)

Poxviridae

VACV

+
(O1)

Polyomaviridae

JCPyV

+
(tAg)

BKPyV

+

Cell Cycle
Dysregulation

+
(tAg)

+

+
(E5)

HPV

Herpesviridae

HSV-1

+

+
(ICP0)

HSV-2

+

+
(ICP10)

EBV
Hepadnaviridae

HBV

Promote Cell
Survival

+

Papillomaviridae

KSHV

Altered Immune
Response

+
(ORF45)
+
(LMP1/2A)
+
(HBx)

+
(MHBs(t))

+
(ICP34.5)

+
(US3)
+
(ICP10)

+
(HBcAg)

Table 1.1. Role of MAPK-ERK in infectious lifecycle of DNA viruses.
(+) indicate viral induction of the MAPK-ERK pathway to facilitate the indicated response, with the
associated viral protein that influences MAPK-ERK signaling indicated (if known).
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Figure 1.4. DNA virus stimulation of the MAPK-ERK cascade.
Viral stimulation of the MAPK-ERK pathway induces sequential phosphorylation of the core kinase of the MAPKERK signaling mechanism: Raf, MEK, and ERK. Upon activation of this pathway, multiple responses can be
induced to help facilitate viral infection including: promoting cell survival, cell cycle dysregulation,
enhancement of viral replication, or alterations to host immune responses. Abbreviations: BK polyomavirus
(BKPyV), Epstein-Barr virus (EBV), human adenovirus (HAdV), hepatitis B virus (HBV), human papillomavirus
(HPV), herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HPV-2), JC polyomavirus (JCPyV), Kaposi’s
sarcoma-associated virus (KSHV), vaccinia virus (VACV). Created with BioRender.

1.6.1. Mitogen-Activated Protein Kinase Cascade
There are four distinct mitogen-activated protein kinase (MAPK) signaling cascades that play
central roles in transmitting and interpreting extracellular stimuli into intracellular responses including:
the extracellular signal-regulated kinase (ERK1/2), p38 MAPK, c-Jun N-terminal kinases (JNK1/2/3), and
ERK5 [76]. The MAPK pathways are comprised of highly conserved serine/threonine kinases that are
activated in response to external stimuli propagated through the phosphorylation of upstream MAP
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kinases [77]. These external stimuli can include hormones, growth factors, stress signals, or even
invading pathogens that often interact with membrane-bound receptors to initiate the signaling cascade
[78]. The MAPK-ERK pathway signals through three core kinases: Raf, MAPK/ERK kinase (MEK1/2), and
ERK1/2, which are responsible for regulating a plethora of cellular responses including differentiation,
proliferation, and survival [79]. Upon stimulation, the upstream MAP kinase kinase kinase (Raf) activates
the MAP kinase kinase (MEK1/2), culminating in the phosphorylation of the MAP kinase (ERK1/2). The
activation of this pathway can induce cellular growth and differentiation by means of upregulating hostcell DNA machineries downstream of phosphorylated ERK (pERK) [80]. Activated ERK1/2 proteins have
been shown to interact with over 200 known cellular substrates, located in both the cytoplasm (RSK,
FAK, MNK, etc.) and within the nucleus (Elk-1, c-Fos, c-Jun, etc.), giving this signaling pathway immense
influence over the fate of the cell [72]. ERK1/2 regulates an array of nuclear transcription factors
through phosphorylation, which in turn can regulate gene expression based upon the initial input
stimulus. Moreover, these ERK-activated transcription factors like the AP-1 complex, can directly
influence cyclins and thus cyclin-dependent kinases (CDKs) that regulate the cell cycle driving cells from
G1 (gap 1, resting) to S (synthesis) phase [78,81]. On the flip side, the MAPK signaling cascade is further
regulated by MAPK phosphatases (MKPs), which can act as negative or positive regulators of MAPK-ERK
signaling. Protein phosphate 2A (PP2A) is essential as a negative regulator of the MAPK pathway through
mechanisms including but not limited to the dephosphorylation of MEK or ERK [82].
1.6.2. Viral Utilization of the MAPK Pathway
1.6.2.1. Adenoviridae
1.6.2.1.1.

Adenovirus

The human adenovirus (HAdV) family is comprised of over 60 different serotypes that infect a
variety of human tissues [83]. While HAdV infections most commonly occur in the upper respiratory
tract, they are also associated with a wide range of clinical diseases such as conjunctivitis, myocarditis,
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and gastroenteritis [83,84]. HAdVs are non-enveloped, double-stranded DNA viruses that range from 70100 nm in diameter [85]. The genome of HAdVs, similar amongst all serotypes, is separated into early,
intermediate, and late gene regions that parallel the infectious lifecycle [85]. The early region is divided
into gene families E1-E4 that initiate viral replication processes. Intermediate transcripts IX and IVa2 are
trailed by the late region, comprised of transcript families L1-L5, which facilitate virion maturation
[83,85]. Interestingly, multiple groups have demonstrated that HAdVs require the induction of MAPKs
like the ERK, p38, and JNK pathways to facilitate the completion of the viral replication process [86-88].
Early investigations into HAdV infection demonstrated that multiple serotypes of HAdV and HAd viral
vectors activate MAPK-ERK signaling, facilitating both host-cell cytokine production and viral replication
[89-93].
Much of the research regarding HAdVs has focused on its implementation as a delivery system
for gene therapies, particularly focusing on elucidating the impacts of these HAdV vectors on hostimmune responses such as the production of cytokines [94]. HAdVs induce the production of proinflammatory cytokines such as interleukin-8 (IL-8), which acts as a chemoattractant to recruit
neutrophils and other immune cells to the site of infection [93]. HAd viral vectors and infectious wildtype HAdV activate the MAPK-ERK pathway upon viral attachment to induce the production of cytokine
interleukin-8 (IL-8) [89-91]. The induction of IL-8 by HAdV-stimulated MAPK-ERK signaling occurs across
multiple cell types and contributes to host-inflammatory responses during gene therapy administration
of HAd viral vectors [89-91,94,95]. IL-8 induction poses a challenge for HAdV vector-mediated treatment
delivery, yet suppression of IL-8 has been demonstrated to improve the efficacy of HAdV oncolytic
vectors in cancer treatments [96]. However, it should also be noted that HAdV infection of polarized
epithelial cells activates the production of IL-8 to upregulate the expression of the viral receptor
coxsackievirus and adenovirus receptor (CAR), resulting in enhanced viral entry, suggesting that IL-8
production may enhance infection with CAR-utilizing HAdVs or vectors [97]. Furthermore, other studies
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have highlighted the role of HAd viral vector-induced MAPK-ERK signaling in the activation of microglia,
the phagocytic immune cells in the CNS [98]. HAdV vectors stimulate the production of nitric oxide (NO)
and inducible NO synthase (iNOS), which activate microglia and the host-immune response [98].
Interestingly, NO and iNOS production is inhibited upon treatment with the MEK inhibitor PD98059,
suggesting that inhibition of ERK activation prevents HAd vector-stimulation of inflammatory responses
common in HAd vector gene therapy models [98]. These works in particular, have helped to
demonstrate the significance of the MAPK-ERK pathway in addressing the immunological consequences
of HAd vector utilization for gene therapies.
More recently, HAdV research has focused on the impact of MAPK-ERK signaling on viral
replication. While activation of MAPK-ERK occurs initially after HAdV challenge [89,92], ERK signaling
facilitates only the later stages of viral infection [88,92]. ERK is activated in a transient and biphasic
pattern in response to HAdV infection [89,92], suggesting that HAdV and HAd vectors induce MAPK-ERK
signaling at various points in the viral lifecycle to promote multiple facets of the viral infection process.
Inhibition of MEK via U0126 treatment reduces the production of viral progeny [92], ribosomal
association with viral mRNA [92], as well as Ras-mediated HAdV replication [99]. Recently work has
investigated the capacity of HAdV protein E4-ORF1, an activator of phosphatidylinositol 3-kinase (PI3K),
to stimulate the MAPK-ERK pathway [100]. In particular, the authors identified the role of MAPK-ERK
activation of the downstream transcription factor cMyc, which was shown to enhance HAdV replication
[100]. The authors found that HAdV E4-ORF1 protein can promote the activation of MAPK-ERK through
the epidermal growth factor receptor (EGFR) specifically to sustain cMyc levels in the nucleus [100].
Together, these findings suggest that HAdV targets activation of MAPK-ERK to facilitate the viral
replication processes [88,92,100].
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1.6.2.2. Poxviridae
1.6.2.2.1.

Vaccinia virus

Vaccinia virus (VACV), the prototypical member of Poxviridae, is a large, enveloped doublestranded DNA virus (360 × 270 × 250 nm in diameter) that is amongst the most complex of mammalian
viruses. With a genome of ~200 kbp in length, VACV encodes for over 200 genes [75,101], including
viral-dependent polymerases, which enable the virus to complete the replication process solely within
the cytoplasm of the infect host cell. VACV, a close evolutionary relative of variola virus, the cause of
smallpox, is utilized in the current smallpox vaccination regimen [102]. Due to the live vaccinia virus
formulation of the vaccine, related complications after exposure include accidental inoculation, the
development of eczema vaccinatum or progressive vaccinia, and myocarditis [102,103]. However, widespread vaccination was halted in the 1970s due to worldwide smallpox eradication, and vaccination is
now limited to laboratory staff and military personnel due to potential bioterror threats [102,104].
VACV infection results in the activation of the MAPK-ERK pathway and the subsequently
produced viral gene products drive sustained MAPK signaling to facilitate viral replication [75]. Over the
course of the infectious process, VACV-infected cells secrete a polypeptide, VACV-induced growth factor
(VGF), that competes for binding to the epidermal growth factor receptor (EGFR) on the cell surface
[105]. Interestingly, prototypical EGFR signaling stimulates mitogenic processes like cellular growth and
proliferation, often through canonical MAPK-ERK signaling [106]. The utilization of EGFR during infection
suggests that VACV could use the mitogenic signaling potential of EGFR to activate the MAPK-ERK
cascade, yet VGF is not required for sustained ERK1/2 activation [107]. Interestingly, the early activation
of the MAPK-ERK pathway facilitates the expression of the viral early gene thymidine kinase (TK), an
enzyme critical for viral replication [108]. Experiments employing the MEK inhibitor PD98059,
demonstrated delayed TK expression and a significant decrease in infectious VACV progeny production,
highlighting the role of MEK and ERK in VACV replication [107,109]. Moreover, VACV promotes
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sustained activation of ERK1/2 through the VACV O1 protein [107,110] and the downstream target
ribosomal S6 kinase 2 (RSK2) in a multiplicity of infection (MOI)-dependent fashion, suggesting
enhanced MAPK-ERK facilitates multiple stages of the viral lifecycle [107,110]. For example, VACVinduced MAPK-ERK activation has downstream impacts on viral replication. Transcription factor targets
of phosphorylated ERK (pERK) such as cFos [75], early growth response 1 (EGR-1) [111], and c-Jun [112],
are temporally regulated by VACV during the infectious lifecycle through direct modulation of MAPKERK in order to dysregulate host-cell functions and promote viral replication [75,111,112]. In sum, VACV
activates the MAPK-ERK pathway upon initial infection to promote the expression of viral proteins like
O1 leading to sustained MAPK-ERK activation, which is necessary for viral replication. These findings
demonstrate the necessity for highly orchestrated MAPK-ERK activation in VACV infection.
1.6.2.3. Polyomaviridae
In recent years, discovery of human polyomaviruses has expanded greatly, with the
identification of over ten new viral species [113-123]. With such rapid discovery of new polyomaviruses,
it is critical that investigations into their potential impacts on human health keep pace. Polyomaviruses
have differing tissue tropisms, yet generally only cause diseases in the immunocompromised [8,124].
Clinical manifestations of polyomavirus infections include a wide range of illnesses such as skin cancer,
polyomavirus-induced nephropathy (PVN), and demyelinating disease of the central nervous system
(CNS) [8,125-127]. Polyomaviruses are icosahedral, non-enveloped viruses that are approximately 40-45
nm in diameter [128]. Each has a circular double-stranded DNA genome that are ~5200 bp in size [128].
The overall structure of the genome is divided into two main sections – early and late viral genes
separated by a non-coding control region (NCCR). The viral early genes (T-antigens) and late genes (viral
proteins 1, 2 and 3 and agnoprotein), are temporally regulated to support productive infection within
the host [8,128]. Encoded within the early region are small t-antigen (tAg), large T-antigen (TAg) and an
alternatively spliced large T-antigen or middle t-antigen (Tag) [10,128]. Of these, TAg plays a crucial role
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in promoting polyomavirus replication through varying biological activities within the cell that help to
facilitate the production of the late viral proteins VP1-3, which comprise the viral capsid [10,128].
Despite the disparity in tissue tropism and disease manifestations, members of the Polyomaviridae
converge at the utilization of the MAPK signaling pathway during infection. Interestingly, in addition to
activation of the MAPK pathway, a number of polyomaviruses encode for proteins that specifically bind
to the protein phosphatases and thus can regulate the activation of the MAPK within the host cell for
viral replication.
1.6.2.3.1.

JC polyomavirus

The human pathogen JC polyomavirus was discovered in 1971 when it was isolated from the
brain of an individual with progressive multifocal leukoencephalopathy (PML) [25]. JCPyV is projected to
infect between 50-80% of the human population, causing a persistent asymptomatic infection in the
kidney of healthy individuals [15,16]. In humans, JCPyV is the etiological agent of PML, a fatal
neurodegenerative disease, characterized by the viral lysis of glial cells, astrocytes and oligodendrocytes,
within the CNS [22,23]. Resultant PML lesions are caused by the destruction of the myelin-producing
glial cells leading to a loss of the myelin sheath on neuronal axons [26]. These lesions are typically
multifocal across varying regions of the brain suggesting that the spread of the virus into the CNS is
hematogenous in nature [26]. Since the onset of the HIV epidemic in the 1980s [129], the majority of
PML cases have been linked to HIV+ individuals. As of 2005, nearly 80% of reported PML diagnoses have
been associated with HIV infection [130].
Research into the infectious process of JCPyV has predominantly been focused on the viral
attachment, internalization, and trafficking mechanisms necessary for infection. However, recent
studies have begun to focus on the importance of viral manipulation of cellular signaling cascades
including MAPK-ERK that facilitate these infectious processes. Signaling mechanisms like MAPK-ERK
transmit extracellular stimuli inward towards downstream cellular targets, often through membrane20

bound proteinaceous receptors. In the case of JCPyV, viral internalization requires the receptors of the
5-hydroxytryptamine subtype 2 family (5-HT2R) [41], receptors that have been linked to the activation of
the MAPK-ERK pathway [131]. Although a direct link between JCPyV and 5-HT2R has not yet been
established, ERK becomes phosphorylated in JCPyV-infected cells at timepoints coinciding with viral
entry, suggesting JCPyV activates the MAPK-ERK pathway early during infection [46,132]. JCPyV-induced
ERK phosphorylation is multiphasic in nature, demonstrating transient activation patterns that appear to
facilitate multiple phases of viral infection [46,132]. However, early activation of ERK is not required for
viral attachment or entry processes, indicating that while JCPyV-induced MAPK-ERK signaling occurs
early on, this pathway plays a role in promoting the later stages of infection such as viral transcription
and overall viral replication [46,132]. Moreover, JCPyV infection has been shown to require receptor
tyrosine kinase (RTK) activity, which may highlight alternate mechanisms for MAPK-ERK activation
during JCPyV infection [46,133].
Multiple reports have indicated that MAPK-ERK activation during JCPyV challenge is required for
successful infection in multiple cell types [46,64,132]. Chemical inhibition of MAPK-ERK proteins,
including Raf (Bay43-9006) and MEK (PD98059, U0126), results in significant reductions in JCPyV
infectivity [46,64,132,134]. This inhibition of ERK activity may play a direct role in preventing ERK nuclear
localization and subsequent activation of the requisite transcription factors needed to facilitate viral
replication. Treatment of glial cells in vitro with ERK siRNA causes a significant reduction in viral early
gene T-antigen transcripts, suggesting that ERK activity plays a role in facilitating the transcription of
viral gene products [132]. Interestingly, protein phosphatase 2 (PP2A), which is known to
dephosphorylate members of MAPK-ERK, physically interacts with JCPyV tAg, which may allow for
sustained activation to these core kinases during infection [59]. Seemingly, JCPyV activation of MAPKERK involves the complex regulation of multiple proteins within and adjacent to the MAPK-ERK pathway
in order to promote dysregulation of canonical signaling and promote viral replication.
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Early studies of JCPyV infection characterized transcription factors that are necessary for viral
replication of early and late genes including SMAD4, cMyc, c-Jun, cFos (AP1), and nuclear factor of
activated T-cells (NFAT4) [65,67,135-138]. Interestingly, many of these identified host-factors are
downstream targets of the activated MAPK-ERK pathway [71]. Previous work has demonstrated that an
activator of the transcription factor SMAD4, TGF-1, stimulates JCPyV replication by increasing SMAD
association with JCPyV promoter sequences [64]. This stimulation however, was blocked by the MEK
inhibitors PD98059 and U0126, suggesting that TGF-1 stimulation of the JCPyV replication process
occurs through the MAPK-ERK pathway [64]. Expression of the early viral gene product TAg, has been
shown to increase NFAT4 activity in glial cells [67], suggesting that the PKC-calcium corridor, an activator
of MAPK-ERK, may also play a role in JCPyV infection. Taken together, these findings suggest that JCPyV
activation of the MAPK pathway may regulate the activation of transcription factors necessary for viral
infection.
1.6.2.3.2.

BK polyomavirus

BK polyomavirus (BKPyV) is the causative agent of polyomavirus-associated nephropathy and
hemorrhagic cystitis in humans, most often associated with complications resulting from kidney
transplants [139]. This virus was first identified in 1971, from a renal transplant recipient who presented
with a case of ureteric stenosis [140]. The majority of infected individuals acquire a primary BKPyV
infection during childhood, resulting in a lifelong, persistent infection, similar to that seen during JCPyV
infection [16]. Interestingly, this closely-related polyomavirus shares 75% sequence homology with
JCPyV [141,142], potentially contributing to similar patterns of transmission, patterns of persistence,
and opportunistic induction of disease states in immunocompromised individuals between
polyomaviruses [141,143].
Similar to JCPyV, expression of BKPyV T-antigen proteins modulates host-cell activity in order to
reprogram host-cell functions towards generating new viral progeny. BKPyV small t-antigen binds to
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PP2A, thus preventing the phosphatase from regulating the MAPK-ERK cascade and stimulating
proliferation [144-146]. Moreover, BKPyV replication is enhanced through MAPK-ERK signal activation,
and chemical inhibition of this pathway with the MEK inhibitor U0126 decreases infection, suggesting
that this virus utilizes the MAPK-ERK pathway specifically to facilitate host-cell infection [147].
Interestingly, BKPyV activation of ERK1/2 also promotes increases in cyclin D1 levels, a key regulator of
the cell cycle [147]. Together these findings suggest that polyomaviruses impact the MAPK-ERK pathway
to control host cell cycle progression to facilitate viral replication.
1.6.2.3.3.

Other polyomaviruses

Interestingly, a number of human polyomaviruses that are associated with specific pathologies
of the skin have been shown to activate or utilize the MAPK cascade resulting in activation of the
transcription factor c-Jun. For instance, human polyomavirus 6 (HPyV6), which infects keratinocytes, is
chronically shed from the skin, and has recently been associated with clinical manifestations of the skin
including pruritic and dyskeratotic dermatoses [148], activates the MAPK cascade during infection [149].
HPyV6 induces MEK-ERK phosphorylation through small T-antigen binding to PP2A, leading to the
upregulation of c-Jun [149]. Activation of MAPK-induced c-Jun is implicated in a number of cancers, and
thus highlights a potential role for HPyV6 in contributions to squamous cell carcinomas [149].
Furthermore, Trichodysplasia Spinulosa (TS) polyomavirus (TSPyV), which causes TS, a rare condition of
the skin that leads to disfigurement [150], encodes for a small T-antigen that leads to hyperactivation of
MEK and ERK and phosphorylation of c-Jun [151]. TSPyV small T-antigen and middle T-antigen bind to
PP2A [148,152], and it is likely that this interaction prevents PP2A from dephosphorylating kinase
targets of the MAPK signaling pathway. Overall, TSPyV activation of the MAPK pathway and resultant cJun phosphorylation likely contributes to cellular proliferation and development of TSPyV lesions [151].
On the other hand, Merkel cell polyomavirus (MCPyV), which can cause Merkel cell carcinoma, a rare
but aggressive form of skin cancer, also upregulates c-Jun phosphorylation but does not activate MEK or
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ERK [153]. In summary, the activation of the MAPK pathways by polyomaviruses can result in
upregulation of c-Jun contributing to proliferative skin pathologies.
1.6.2.4. Papillomaviridae
1.6.2.4.1.

Human papillomaviruses

Human papillomaviruses (HPV) of the Papillomaviridae family are small, non-enveloped, doublestranded DNA viruses, most often associated with cervical cancer development [154,155]. The typical
HPV virion is ~60 nm in diameter encasing a circular, double-stranded DNA genome of ~8kb that
encodes for eight proteins [154,155]. HPVs predominantly infect either cutaneous or mucosal surfaces
which leads to the development of a variety of skin pathologies and cancers [156]. HPV infection of
cutaneous regions can cause warts including common and plantar warts as well as rare forms of skin
cancer [156]. Infection of mucosal surfaces, results in disease pathologies more commonly associated
with HPV infection including: condyloma acuminatum, cervical cancer, and head and neck cancers [156].
Remarkably, there are more than 200 identified papillomaviruses [156,157], further classified into lowrisk or high-risk HPV types based on their association with cancer development [156,157]. There are 14
or more high-risk types of HPV that can cause abnormal cellular changes to the cervix, yet types 16 and
18 are responsible for ~70% of cervical cancers [158] and are the most prevalent HPV types worldwide
[159]. Due to their high prevalence and link to human cancers, the high-risk HPV types have been widely
studied to define mechanisms of pathogenicity and carcinogenesis.
Cancer development during HPV infection has been strongly linked to the overexpression of the
viral early genes E6 and E7 [160]. These viral oncogenes promote the dysregulation of the cell-cycle,
prevention of apoptosis, and the initiation of cell proliferation mechanisms, roles central to productive
HPV infection and the resultant development of a variety of cancers [161]. HPV E7 targets numerous cell
cycle control proteins for degradation, including the retinoblastoma (Rb) protein family, leading to
cellular proliferation, while E6 targets the tumor suppressor p53 for degradation, and thus promotes
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immortalization and cellular transformation [162]. The degradation of p53 occurs upon E6 binding and
involves the utilization of the ubiquitin-dependent protease system, leading to a significant loss of tumor
suppression signaling in HPV infected cells [163]. In addition, HPV16 E6 and E7 interact with the MAPKERK pathway during infection [164-167]. Previous reports have identified that in vitro overexpression of
the HPV16 E6 and E7 proteins resulted in prolonged levels of enhanced ERK phosphorylation during HPV
infection, which was subsequently abrogated upon chemical inhibition of MEK with U0126 treatment
[168-170]. Interestingly, the development of HPV-induced cancers has also been linked to the
upregulation of two key mitogenic pathways including EGFR signaling and the stimulation of vascular
endothelial growth factor (VEGF) by the multifunctional viral protein E5. [171-175]. HPV16 E5
upregulates VEGF expression through the activation of ERK, an effect dampened upon chemical
inhibition of ERK phosphorylation with U0126 [173]. In addition to the upregulation of VEGF, E5
stabilizes EGFR leading to an enhancement of MAPK-ERK signaling [176]. Additional works have
implicated the E5 protein in providing protection from apoptosis and autophagy in HPV-infected cells
through the utilization of the MAPK-ERK cascade [177-179]. The overexpression and enhanced
stimulation of EGFR upon HPV infection has also been well-documented and has been shown to result in
the phosphorylation of ERK [176,180-182]. Further, HPV utilization of the EGF receptor is required for
HPV E6 splicing, and this process is dependent on ERK signaling, as treatment with U0126 or
overexpression of a dominant-negative MEK1 resulted in enhanced E6 exon exclusion [183]. Ultimately,
these findings demonstrate the role of MAPK-ERK in promoting critical steps in HPV infection including
host-cell survival, which can ultimately result in the development of HPV-induced human cancers.
1.6.2.5. Herpesviridae
Herpesviridae comprise a large family of viruses with nine virus species that routinely infect
humans. They are characterized as large enveloped double-stranded DNA viruses with a virion diameter
ranging from 100-300 nm with a unique and complex icosahedral structure [184]. The unique four25

layered structure includes an envelope decorated with viral glycoproteins underlaid by a tegument
layer, a nucleocapsid, and a core, which houses the viral genome. Linear herpesvirus genomes range in
size from 125-240 kbp with ~70-170 protein-coding genes [185]. Gene expression is temporally
regulated during the infectious cycle, and thus the viral genes are appropriately deemed: immediate
early (IE), early, and late genes [186]. The IE genes are expressed immediately upon infection and are
necessary to activate the early genes, which drive DNA replication, and the late genes which provide the
structural components. A further defining feature of herpesviruses is that in addition to the lytic
replication cycle, they can establish latency within the host with periodic episodes of reactivation [186].
Due to the large size and variation in herpesviruses genomes, it is not surprising that this family of
viruses has a broad tissue tropism and can cause a wide range of outcomes in the human host. Thus,
herpesviruses are organized into three subfamilies: alpha, beta, and gamma based on their sizes and
sites of latency.
Alphaherpesvirues generally infect epidermal cells and establish latency in the sensory neurons.
Betaherpesviruses have a broad tropism for tissues including lymphocytes, secretory glands and the
kidney. Finally, gammaherpesviruses have the narrowest host range, replicating in lymphoblast B and T
cells [187]. Despite the broad range in virion and genome size, tissue tropism, and disease outcomes, a
number of herpesviruses utilize the MAPK-ERK pathway to facilitate a successful viral infection.
1.6.2.5.1.

Herpes simplex virus

Herpes simplex virus 1 and 2 (HSVs) are members of the Alphaherpesvirinae, defined by
relatively short infectious cycles and dynamic replication pattern [187,188]. The enveloped virions of
HSV-1 and HSV-2 are ~200 nm in diameter [189,190]. HSVs cause oral and genital lesions, and, in rare
cases, viral encephalitis [191]. The seroprevalence of HSV-1 across the globe is estimated to be ~90%
[192], significantly higher than that of HSV-2 [193]. Some human herpesviruses are both oncogenic
(tumor forming) and oncomodulatory (modulate tumor behavior), due in large part to the establishment
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of latency within the host cell [194]. Upon exposure, HSVs will induce latent infections in the neuronal
sensory ganglia, maintained throughout the lifetime of the host, with periodic cycles of lytic reactivation
[188].
The HSV-1 and HSV-2 genomes comprise over 70 distinct protein-coding genes that encode for
proteins such as glycoprotein B (gB) and the infected cell proteins (ICPx) [184]. Interestingly, reactivation
of HSV-1 into a lytic state requires the expression of IE genes within infected cells [195]. The
accumulation of IE gene products drives viral early gene transcription and subsequent replication,
resulting in the lytic infectious program. The complexity of the HSV-1 infectious lifecycle can be
appreciated through the examination of HSV-1-induction of the MAPK-ERK pathway. Dysregulation and
manipulation of MAPK-ERK signaling cascade facilitates multiple steps in the viral lifecycle including
dampening of the host-cell anti-viral response, viral replication, and cell cycle control [194,196-198].
In order to facilitate infection, HSV-1 temporally regulates gene expression, which influences a
spatial and progressive regulation of specific cellular proteins. Within the first 15 minutes of HSV-1
challenge, levels of pERK significantly increase, which are predominantly localized to the cytoplasm of
the infected cell [198]. However, at later stages of infection congruent with viral replication, both pERK
and ICP0, a multifunctional IE gene, localize to the nucleus, suggesting that ICP0 function requires ERK
activity [198]. ICP0 function has predominantly been associated with cell cycle regulation within cells
infected with HSV-1, through cyclin D3 [199,200]. Through the implementation of dominant-negative
ERK1 constructs, Colao et al. demonstrated that ERK1 activity is necessary for cell cycle control during
HSV-1 infection, which is in turn required for viral replication [198]. Interestingly, HSV-1 infection also
requires cyclin E and the cyclin-dependent kinases (CDK) 2 and 5 for infection, suggesting further viral
influence over the cell cycle and viral replication [198,201,202]. HSV-2 also utilizes the MAPK-ERK
pathway to dysregulate the cell cycle, specifically through ribonucleotide reductase R1 protein (ICP10),

27

to induce a proliferative cellular state [194,203,204], demonstrating the conserved utilization of the
MAPK-ERK pathway for cell cycle dysregulation between these human herpesviruses.
Antiviral immune responses activated upon infection are important mechanisms that allow the
host to recognize foreign pathogens. Activation of pattern-recognition receptors like toll-like receptors
(TLRs) initiate the production of the antiviral signaling protein interferon (IFN), which is secreted from
infected cells. IFN binding to IFN receptors on the same or neighboring cells, activates the IFN signaling
pathway resulting in activation of IFN-stimulated genes such as the protein kinase regulated by dsRNA
(PKR). PKR phosphorylates eIF2α resulting in halted protein translation, which is an effective way of
protecting the cell from production of viral proteins. Productive HSV-1 infection requires the inhibition
of PKR, via viral protein ICP34.5 and MAPK-ERK activity, which prevents the phosphorylation and
subsequent deactivation of the eIF2α complex [194,196,197]. Inhibition of MEK with the chemical
inhibitor PD98059 resulted in decreased levels of pERK, increased levels of PKR phosphorylation, and
subsequent loss of late viral protein accumulation [205].
Additional studies have identified regulation of cellular anti-apoptotic activity during HSV
infection via the viral gene US3 [206-209], a protein that has been shown to inhibit the MAPK-ERK
pathway [209]. Conversely, the large subunit of HSV-2 ribonucleotide reductase, ICP10, induces ERK
activity in order to block JNK-stimulated apoptotic signaling in hippocampal neurons [210]. Through the
activation of Bag-1, ICP10-induced ERK is able to override these cell death signals, indicating a prosurvival implementation of the MAPK-ERK cascade during HSV-2 infection [210]. These broad
mechanisms highlight multidimensional applications of the MAPK-ERK pathway utilized by HSV proteins.
Beyond regulation of the cell cycle and pro-survival signaling, the MAPK-ERK pathway also
facilitates the process of viral replication. During HSV-2 infection, ERK activation occurs during the early
steps of viral infection and is sustained through 24 hours post infection [205,211]. When
phosphorylation of ERK is inhibited by U0126 or MEK1/2 siRNA treatment, HSV-2 propagation is
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decreased as measured by the production of viral proteins UL30 and gB [211]. These findings suggest
that HSV-2 upregulates MAPK-ERK signaling to promote viral replication [211]. HSV-2 infection
specifically activates components of the MAPK-ERK pathway including Ras, ERK, and the downstream
transcription factor target, cFos [212], indicating that HSVs dysregulate MAPK-ERK to dampen the
immune response, dysregulate the cell cycle and induce pro-survival signaling, but can also utilize this
cascade to facilitate replication of the viral genome.
1.6.2.5.2.

Kaposi’s sarcoma-associated herpesvirus

The oncogenic Kaposi’s sarcoma-associated herpes virus (KSHV), of the Gammaherpesvirinae
subfamily, was first identified in 1994 [213]. Associated with the disease from which the name was
derived, Kaposi’s sarcoma (KS) results in soft tissue tumors and has also been linked to the development
of primary effusion lymphoma (PEL) [214]. KSHV has a genome of ~170 kbp in length, which encodes for
a variety of latent, early lytic, and late lytic proteins [215]. KSHV DNA is present in all KS tumors often in
conjunction with HIV, however, this is not a prerequisite for KS tumor formation [216]. Like other
herpesviruses, KSHV adopts either a latent or lytic gene expression pattern, with lytic replication
induced by the expression of the replication and transcription activator (RTA) viral protein [216].
Interestingly, activation of RTA can be induced in vitro through chemical application of phorbol esters
like TPA (12-O-tetradecanoyl-phorbol-13-acetate) [217-221]. TPA is also associated with the stimulation
of the MAPK-ERK signaling pathway through activation of protein kinase C [220], potentially linking
MAPK-ERK signaling with KSHV entrance into the lytic replication phase [217].
A key member of the MAPK-ERK pathway, Raf, was identified as playing a critical role in
promoting KSHV infection [222]. Interestingly, inhibition of MAPK-ERK signaling through treatment with
PD98059 and U0126, as well as bRaf siRNA treatment demonstrated that inhibition of MAPK-ERK
signaling prevented KSHV reactivation [217,218,220,223,224]. Activation of MAPK-ERK signaling occurs
early in the infectious cycle, within minutes of viral challenge, but is not required for viral attachment or
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internalization [223-225], similar to the activation pattern of the aforementioned JCPyV [46,132].
Increased MEK and ERK activity also plays a role in facilitating transcription of viral genes such as ORF8,
ORF50, ORF73, and gB [220,225] upon nuclear localization of ERK [225]. The activation of MAPK-ERK
during infection does increase RTA activity [223], but is also linked to KSHV utilization of transcription
factors downstream of MAPK-ERK, such as the c-Jun, cFos, and cMyc [223,225,226]. The immediate early
lytic protein ORF45, binds to and activates RSK, preventing the dephosphorylation of both ERK and RSK
[226-228]. Cumulatively, these findings demonstrate that KSHV infection drives MAPK-ERK signaling to
promote the reactivation from latency to promote the production of infectious progeny.
1.6.2.5.3.

Epstein-Barr virus

Epstein-Barr virus (EBV), the prototype member of the Gammaherpesvirinae subfamily, infects
~90% of the world human population [229]. EBV, most commonly associated with mononucleosis, was
first isolated in 1964 from a case of Burkitt lymphoma [230]. More recently, EBV has been associated
with other malignancies including nasopharyngeal carcinoma (NPC), as well as non-Hodgkin’s and
Hodgkin’s lymphomas [229]. EBV infects memory B cells, a viral tactic to evade the host-immune system,
that helps in facilitating the development of a latent infection [231,232]. The EBV genome encodes for
~80 genes related to both latent and lytic infectious cycles [233]. The establishment and maintenance of
the latent infection requires the expression of EBV latency genes such as: the latent membrane proteins
(LMP) LMP1, LMP2A, and LMP2B [233].
The latent infection of primary B cells by EBV and subsequent cellular transformation requires
activation of MAPK-ERK signaling by LMP1 [234]. ERK activity is induced by LMP1, mediated through Ras
signaling [234,235]. EBV-induced activation of MEK and ERK plays a role in increasing EBV infectivity as
well as facilitating the reactivation of latent EBV [235]. Inhibition of proteins within the MAPK-ERK
pathway have been shown to decrease EBV infectivity as well as induce a negative effect on EBVinfected B cell viability [236]. LMP1 plays a significant role in promoting epithelial cell invasion, an
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oncogenic property that may contribute to EBV-induced tumor formation. Interestingly, the ability of
LMP1 to promote cell invasion and motility requires the MAPK-ERK pathway, suggesting that EBV
manipulation of this signaling pathway not only promotes infection through downstream activation of
transcription factors like the AP-1 complex, but may also promote viral pathogenesis within the host
[237,238].
LMP2A is another EBV latency protein that impacts the MAPK-ERK pathway to promote
infection. Previous research has identified that this protein both phosphorylates and is phosphorylated
by ERK [239-241]. These activation patterns may suggest that ERK activation of LMP2A may be necessary
to facilitate LMP2A-mediated cell migration, or that LMP2A activates ERK in order to influence
downstream transcription factor targets like c-Jun [240]. Both LMP1 and LMP2A are EBV proteins that
help to maintain viral latency, typically in primary B lymphocytes [234]. Through altering mechanisms of
MAPK-ERK activation, these proteins may be required for facilitating multiple facets of the latent
infection within the B cell microenvironment.
1.6.2.6. Hepadnaviridae
1.6.2.6.1.

Hepatitis B Virus

Hepatitis B virus (HBV) is the prototype member of the Hepadnavirus family and named for
causation of hepatitis [242]. Chronic HBV infection is associated with cirrhosis of the liver and
hepatocellular carcinoma [242-245]. The intact enveloped virion is ~42 nm in diameter [246] and
contains a gapped, partially double-stranded DNA genome of ~3000 bp in length. Interestingly, the HBV
genome encodes an encapsidated DNA polymerase, that is covalently linked to the viral genome, one of
the unique and defining features of hepadnaviridae [247,248]. The HBV genome encodes for seven
proteins: preCore, Core, pol, HBx, and the envelope proteins L, M, and S. HBx, a multifunctional
regulatory transactivating protein, targets a variety of cellular substrates to induce cell cycle progression
including the MAPK-ERK pathway [74,249]. HBx plays an essential role in the development of
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hepatocellular carcinoma (HCC), a disease most closely associated with chronic HBV infection
[246,250,251]. While the HBx protein plays many different roles over the course of infection, it is
involved in the dysregulation of signaling mechanisms such as MAPK-ERK to promote several different
stages of HBV infection [74,251]. HBx directly activates the MAPK-ERK pathway [252] through the
activation of Ras, leading to cell progression into the S phase [251] initiating a proliferative cellular state
through the upregulation of cyclin D1 [252]. While HBx does not directly phosphorylate ERK, it does
activate a transcription factor target of MAPK-ERK signaling, c-Jun [253]. Moreover, the middle surface
antigen (MHBs(t)) has been shown to upregulate activation of MAPK-ERK through PKC-dependent
signaling in order to dysregulate the cell cycle [254].
Recently, the HBV core antigen protein (HBcAg) has been shown to induce IL-6 cytokine
production through the activation of the MAPK-ERK pathway in hepatocytes [255]. The activation of this
cytokine is blocked during chemical treatment with the MAPK inhibitor U0126, suggesting that MAPKERK signaling facilitates HBcAg induction of IL-6 [255]. As IL-6 plays an integral role in the development
of hepatocyte inflammation, liver disease, and liver cancers, the utilization of the MAPK-ERK during HBV
infection may highlight a potential role of this pathway facilitating the development of HCC and other
liver cancers in vivo. Indeed, within the mouse model, the multifunctional HBx protein activates ERK,
which can be ablated during treatment with the MEK inhibitor PD98059 [256]. This ERK activation is
sustained in vivo for nearly 30 days, resulting in persistent AP-1 complex activation [256]. These findings
suggest that multiple HBV proteins target the MAPK-ERK pathway to alter cell cycle progression and
increase the activity of specific MAPK-induced transcription factors.
1.7. Summary
JCPyV is a significant human pathogen with the capacity to cause a fatal, demyelinating disease for
which there are no treatments. Viruses usurp cellular factors and pathways in order to invade host cells
and reprogram cells into viral factories for productive infection. Prior to the works described herein,
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little was known regarding JCPyV manipulation of cellular signaling cascades during infection. Moreover,
information regarding JCPyV and the MAPK-ERK pathway was even more scarce. However, preliminary
work from Querbes et al. demonstrated an increase in phosphorylated ERK during early timepoints
during infection, results that did not control for basal levels of ERK activation in mock-infected cells [46].
It was these initial data sets that launched our investigation into the role of MAPK-ERK signaling in JCPyV
infection. Our findings include two predominant arcs: characterizing the role of ERK in promoting the
JCPyV infectious lifecycle and the consequences of this activation on downstream MAPK-ERK effectors.
We have found that the potent signaling molecule ERK, is activated at multiple steps in the viral lifecycle,
but is critical for transcription of the viral genome. Moreover, the activation of the additional core
kinases of MAPK-ERK, Raf and MEK, are also required for infection. The activation of this pathway upon
JCPyV challenge extends to proteins downstream of the MAPK-ERK cascade including transcription
factors that are upregulated upon infection. These transcription factors not only play critical roles in
facilitating infection, but are seemingly recruited and activated by MAPK-ERK signaling. These works
have not only identified the importance of the MAPK-ERK pathway in JCPyV infection, but may provide
insight into antiviral targets for JCPyV treatment and perhaps other viruses that utilize the MAPK-ERK
cascade.
The regulation of the MAPK-ERK pathway by DNA viruses is dynamic in nature, highlighted by both
the similar and differential utilization of this pathway by closely-related viruses. As described (Section
1.6), multiple members of the Polyomaviridae family of viruses stimulate MAPK-ERK activation through
viral disruption of MAPK-ERK regulators like PP2A, to facilitate viral genome transcription and replication
[59,144-146]. MAPK-ERK plays an integral role in many different biological processes, and it is the sheer
complexity of this interconnected signaling network that allows for a multitude of cellular endgames for
a virus to exploit, many of which have significant consequences on the overall health of the host.
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CHAPTER 2
ERK IS A CRITICAL REGULATOR OF JC POLYOMAVIRUS INFECTION
This chapter represents a modified form of the published work from: DuShane JK, Wilczek MP, Mayberry
CL, Maginnis MS. 2018. ERK is a critical regulator of JC polyomavirus infection. J Virol 92:e0152917. Reproduction of the published work for thesis is permitted by the publisher American Society for
Microbiology.
2.1. Chapter Summary
The human JC polyomavirus infects the majority of the population worldwide and presents as an
asymptomatic, persistent infection in the kidney. In individuals who are immunocompromised, JCPyV
can become reactivated and cause a lytic infection in the central nervous system resulting in the fatal,
demyelinating disease progressive multifocal leukoencephalopathy. Infection is initiated by interactions
between the capsid protein viral protein 1 and the α2,6-linked sialic acid on LSTc, while JCPyV
internalization is facilitated by 5-hydroxytryptamine 2 receptors. The mechanisms by which the
serotonin receptors mediate virus entry and the signaling cascades required to drive viral infection
remain poorly understood. JCPyV was previously shown to induce phosphorylation of extracellular
signal-regulated kinase (ERK), a downstream target of the mitogen-activated protein kinase (MAPK)
pathway, upon virus entry. However, it remained unclear whether ERK activation was required for JCPyV
infection. Both ERK-specific siRNA and ERK inhibitor treatments resulted in significantly diminished
JCPyV infection in both kidney and glial cells, yet had no effect on the infectivity of polyomavirus simian
virus 40. Experiments characterizing the role of ERK during steps in the viral life cycle indicate that ERK
activation is required for viral transcription as demonstrated by a significant reduction in production of
the early viral gene large T-antigen, a key viral protein associated with the initiation of viral transcription
and viral replication. These findings delineate the role of the MAPK-ERK signaling pathway in JCPyV
infection, elucidating how the virus reprograms the host cell to promote viral pathogenesis.
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2.2. Introduction
The cellular signaling events activated in host cells in response to JCPyV infection and how they
regulate viral infection and pathogenesis are poorly understood. Querbes et al. demonstrated that
JCPyV requires tyrosine kinase activity for infection as genistein, a broad-spectrum tyrosine kinase
inhibitor, blocks JCPyV infection. Furthermore, the mitogen-activated protein kinase (MAPK),
extracellular signal-regulated kinase (ERK), is immediately phosphorylated 15 min following infection
[46], a time that is consistent with viral attachment and entry events [51]. ERK phosphorylation was
shown to be sustained for 6 h following infection [46]. This indicates that ERK might impact multiple
steps in the virus life cycle including entry and trafficking as JCPyV is localized in the ER at 6 h postinfection, where it is thought to undergo partial uncoating [46,48]. These findings suggest that JCPyV
may usurp MAPK-ERK pathway functions to drive the infectious life cycle, yet the direct impact of the
MAPK pathway on the infectious life cycle of JCPyV has not been fully characterized.
The MAPK signaling pathway induces cellular reprogramming in response to extracellular stimuli
such as growth factors or neurotransmitters [131,257] through a series of phosphorylation events driven
by the MAPK kinases (MAPKKs or MEKs). The small GTPase Ras binds to the serine/threonine kinase Raf
(MAPKKK), which phosphorylates the MAPKKs MEK 1/2 [71,258-260]. The dual specificity kinases MEK1
and MEK2 then phosphorylate ERK1/2 [261-263]. Phosphorylated ERK activates downstream signaling
targets, becomes dephosphorylated by protein phosphatases, or translocates to the nucleus to regulate
transcription factors that function in cell proliferation, differentiation, and cell death [263].
Both DNA and RNA viruses have been reported to activate the MAPK-ERK signal transduction
pathway and in some cases utilize it for infectivity [73], including members of the Polyomaviridae family
[60,147,264]. Activation of the MAPK pathway by BK polyomavirus enhances viral replication [147], but
BKPyV does not activate the MAPK pathway directly [265]. Conversely, mouse polyomavirus (MPyV)
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activates the MAPK-ERK pathway [60,264], but does not require activation of the MAPK pathway for
infection [264]. Furthermore, SV40 polyomavirus activates a MAPK-ERK-independent signaling pathway
that induces Ca2+ mobilization and tyrosine kinase activity of PKC [60,266]. The MAPK-ERK pathway has
been proposed to play a role in JCPyV infection [46,64], yet the impact of MAPK activation on the
infectious viral life cycle remained unclear as polyomavirus activation of the MAPK pathway is
multifactorial and may play critical roles in viral infectivity or could be dispensable.
The goal of this study was to define whether activation of the MAPK-ERK pathway is required for
JCPyV infection and to define the steps in the virus life cycle that are impacted by ERK activation. JCPyV
infection was significantly reduced in cells expressing ERK1/2-specific siRNA and in cells treated with
inhibitors of MEK, which prevent ERK phosphorylation, yet had no impact on SV40 infection. JCPyV
induced ERK activation immediately upon infection, and a MEK inhibitor reduced JCPyV infection within
0-4 h post-infection. However, inhibition of ERK had no impact on the early steps in the viral life cycle
including attachment or entry, yet resulted in reduced activity of the viral early and late promoters and
reduced T-antigen gene expression. These findings demonstrate that activation of the M signaling
pathway is required for driving JCPyV infection and that this pathway is used to reprogram host cells for
viral transcription.
2.3. Materials and Methods
2.3.1. Cells, viruses, antibodies, and reagents
SVG-A cells [267] were cultured in Minimum Essential Medium (MEM) (Corning) supplemented
with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin (P/S) (Mediatech, Inc.) and 0.2%
Plasmocin prophylactic (Invivogen) (complete media). HEK293A-5-HT2AR cells were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5g/L glucose, L-glutamine, and sodium pyruvate
(Corning) supplemented with 10% fetal bovine serum (FBS) and1% penicillin/streptomycin (P/S)
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(Mediatech, Inc.) (complete media). Normal human renal proximal tubule epithelial cells (RPTECs) were
cultured in renal epithelial cell basal medium (REBM) supplemented with 1% P/S and renal epithelial cell
growth kit as suggested by the manufacturer (ATCC). All cells were grown in a humidified incubator at
37°C with 5% CO2. SVG-A cells, RPTECs [268], and HEK293A-5-HT2AR cells [41] were generously provided
by the Atwood laboratory (Brown University) and authenticated by the ATCC.
Generation and propagation of the virus strain Mad-1/SVE and SV40 strain 777 (provided from
the Atwood laboratory (Brown University)) was previously described [269,270]. The Mad-1/SVE was
previously generated through insertion of the SV40 regulatory region (RR) into the Mad-1 RR (Mad1/SVE) and propagation in SVG-A cells which yielded strain Mad-1/SVE with a rearranged RR with the
JC ori, TATA box, and 78 bp of the 98 bp repeat and a SV40 72 bp repeat with the deletion of most other
SV40 72 bp repeats [269]. JCPyV was labeled with Alexa 488 (Thermo Fisher Scientific) according to
manufacturer’s instructions as previously described [271]. The infectious viral clones used for
transfection were genomic JCPyV DNA of strain JC12, a subclone of Mad-1-SVEΔ [269] subcloned into
puc19 at BamHI sites as previously described [272] and genomic SV40 of strain 776 subcloned into
puc19 at EcoRI sites (provided by the Atwood laboratory, Brown University).
MEK inhibitor U0126 (Cell Signaling Technology) and MEK inhibitor PD98059 (Cell Signaling
Technology) were reconstituted in DMSO and used at indicated concentrations at time points specified
prior to or following infection. Antibodies used for indirect immunofluorescence assays include PAB597,
a hybridoma supernatant that produces a monoclonal antibody against JCPyV VP1 (generously provided
by Ed Harlow) [35] that also cross-reacts with SV40 VP1, or PAB962, a JCPyV-specific T-antigen antibody
that does not cross-react with SV40 T-antigen (generously provided by the Tevethia laboratory (Penn
State University)) [34], or AB2 (Calbiochem) to detect SV40 large T-antigen [34] and secondary antimouse Alexa Fluor polyclonal 488 and 594 antibodies (Thermo Fisher Scientific). Antibodies used for
37

western blot analysis were a rabbit-specific antibody specific for total ERK (Cell Signaling Technology
#4695) and polyclonal antibody for tubulin (loading control) (Abcam) and corresponding secondary antimouse 680 antibody (LICOR or Invitrogen) or goat anti-rabbit 800 antibody (LICOR). Antibodies used for
phospho-ERK western blot analysis were a rabbit-specific phosphorylated ERK antibody (Cell Signaling
Technology #9101) and mouse-specific total ERK antibody (Cell Signaling Technology #4696) and
corresponding secondary anti-mouse 680 antibody (LICOR) and goat anti-rabbit 800 antibody (LICOR).
2.3.2. siRNA treatment
SVG-A and HEK293A-5-HT2AR cells were plated to ~50% confluence in 12 well plates (Grenier
Bio-One) and transfected with siRNAs specific for ERK1/2, scrambled control, or EGF receptor control
(Cell Signaling Technology) (7.5 pmol final concentration of siRNA per well) using RNAiMax transfection
reagent (Invitrogen) by mixing transfection complexes in serum- and antibiotic-free MEM or DMEM
(Corning) and incubating at room temperature (RT) for 10 min. Complexes were added to cells and
incubated at 37°C for 48 h. Transfection efficiency was monitored using Block-iT Alexa Fluor Red Control
oligo (Life Technologies), and optimum ERK protein reduction was confirmed by protein quantitation
through western blot analysis. At 48 h post-transfection, cells were infected with JCPyV or SV40.
2.3.3. siRNA western blot analysis
To analyze siRNA knockdown, cells were washed in PBS, scraped from wells, washed in PBS, and
pelleted by centrifugation at 376 x g at 4°C for 5 min. Cell pellets were resuspended in 30 μl of Tris-HCl
lysis buffer containing protease and phosphatase inhibitors, incubated on ice for 20 min, then insoluble
material was removed by centrifugation at 18,600 x g at 4°C for 10 min. Samples were mixed with
Laemmli sample buffer (Bio-Rad) and resolved by SDS-PAGE using a 4-15% gel (Bio-Rad). Proteins were
transferred to a PVDF membrane using a Transblot Turbo Transfer System (Bio-Rad) at 10V for 30 min.
The membrane was blocked with 5% non-fat dry milk/PBS-T (1X PBS/0.05% Tween 20) overnight (O/N),
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then washed in PBS-T at RT extensively, and incubated with an antibody specific for total ERK (1:500)
(Cell Signaling Technology) and polyclonal antibody for tubulin (loading control) (1:450) (Abcam) in 5%
BSA/PBS-T O/N at 4°C, rocking. Membranes were washed in PBS-T at RT, then incubated with a
secondary anti-rabbit 800 antibody (1:5000) (LICOR) or anti-mouse 680 antibody (1:1000) (Invitrogen) or
at RT for 1 h in 5% milk/PBS-T. Membranes were washed in PBS-T and PBS then imaged using a LICOR
Odyssey CLx.
2.3.4. JCPyV and SV40 infection
Following treatments with inhibitors, vehicle controls, or transfection with siRNAs, media was
removed and cells were infected with JCPyV or SV40 (MOIs indicated in figure legends). SVG-A cells were
infected in MEM containing either 2% or 10% FBS at ~70% confluence. HEK293A-5-HT2AR cells were
infected in complete DMEM containing 10% FBS at ~50% confluence. Infection of RPTECs was completed
in REBM at ~75% confluence. Prior to RPTEC experiments, 96 well plates were pretreated with laminin
from human fibroblasts (Sigma-Aldrich) at 1 µg/cm2 at 37°C for 1 h. Viral infections were completed in
volumes of either 200 L (24 well plate) or 40 L (96 well plate), and incubated at 37C for 1 h, then
indicated treated or untreated media was added and cells were incubated at 37C for 48 h (T-antigen) or
72 h (VP1). Cells were then fixed and stained by indirect immunofluorescence.
2.3.5. Variable timing of ERK inhibition during JCPyV infection
SVG-A cells were pre-treated (PT) for 1 h prior to JCPyV infection with U0126 (10µM) or DMSO
(1:1000), or incubated in complete media as indicated. Cells were then infected with JCPyV at 37°C for 1
h. Following infection, cells were incubated in media containing either U0126 or DMSO for the indicated
duration. For 1 h and 4 h samples, treatment media was removed at the indicated timepoint, complete
media was added, and cells were incubated at 37°C for the duration of the infection (72 h). Cells were
fixed and stained by indirect immunofluorescence using a VP1-specific antibody that recognizes JCPyV
VP1. Infectivity was scored by quantitating nuclear VP1 expression.
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2.3.6. Western blot quantitation of ERK phosphorylation during JCPyV infection
SVG-A cells at 95% confluency (6 well plates) were either infected with JCPyV (MOI = 1 FFU/cell)
or mock infected (complete media), and incubated at 37°C for indicated timepoints or immediately
harvested (0 min). For timepoints exceeding 1 h, both mock-treated and infected-cells were fed with 1
mL of complete media after 1 h infection and incubated at 37°C. At the specified timepoint, cells were
washed in 1XPBS, scraped from wells on ice, and pelleted by centrifugation at 376 x g at 4°C for 5 min.
Cell pellets were resuspended in 50 μl of Tris-HCl lysis buffer containing protease and phosphatase
inhibitors, incubated on ice for 15 min, and insoluble material removed by centrifugation at 18,600 x g at
4°C for 10 min. Samples were mixed with Laemmli sample buffer (Bio-Rad), incubated at 95°C for 5 min,
then resolved by SDS-PAGE using a 4-15% Mini TGX gel (Bio-Rad). Proteins were transferred to
nitrocellulose membranes using a Transblot Turbo System (Bio-Rad) at 25V for 3 min. The membrane
was blocked with 5% non-fat dry milk/TBS-T (1X TBS/0.05% Tween 20) rocking at RT for 1h, then washed
in TBS-T at RT, and incubated with a rabbit-specific antibody specific for phosphorylated ERK (1:1000)
(Cell Signaling Technology #9101) and mouse-specific antibody targeting total ERK (1:1000) (total ERK
protein control) (Cell Signaling Technology #4696) in 5% BSA/TBS-T rocking at 4°C O/N. Membranes
were then washed in TBS-T at RT, and incubated with both secondary anti-mouse 680 antibody
(1:15,000) (LICOR) and goat anti-rabbit 800 antibody (1:15,000) (LICOR) rocking at RT for 1 h in 5% nonfat dry milk/TBS-T. Membranes were washed in TBS, then imaged using a LICOR Odyssey CLx.
Quantitation of phosphorylated ERK and total ERK expression was performed via analysis of LICOR 680
and 800 intensities corresponding to the total and pERK antibodies using LICOR Odyssey CLx Image
Studio software Version 5.2. The percentage of phosphorylated ERK was then quantitated by calculating
(phosphorylated ERK/ (phosphorylated ERK + Total ERK)) x 100. JCPyV-infected samples within each
timepoint were normalized to mock control samples (100%). Average normalized percentages of
phosphorylated ERK for each treatment were plotted via box-and-whisker plot, representing the
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composite of three independent experiments. Data are representative of the maximum (upper whisker),
median, and minimum (lower whisker) of % phosphorylated ERK from JCPyV-infected samples.
2.3.7. Transfection of JCPyV and SV40 infectious clones
SVG-A cells were plated to ~50% confluence in 24 well plates (Grenier Bio-One). Cells were pretreated for 1 h with medium containing either DMSO (1:1000) or U0126 (10 M). Cells in medium
without antibiotics were transfected with 1 g of JCPyV-puc19 or SV40-puc19 plasmid DNA that had
been linearized through digestion with BamHI (JCPyV-puc19) (Promega) or EcoRI (SV40-puc19)
(Promega) at 37C for 2 h using Fugene (Roche) at 1.5:1 ratio (Fugene:DNA) [35] and incubated at 37C.
At 24 h post-transfection, cells were fed with 500l of complete media containing 1% amphotericin B
and either DMSO (1:1000) or U0126 (10 M) and incubated at 37C. Cells were fixed and stained by
indirect immunofluorescence using a VP1-specific antibody at days 4 and 7 post-transfection.
2.3.8. Indirect immunofluorescence quantitation of viral infectivity
Following infection, SVG-A cells were washed in PBS, fixed in ice cold methanol and incubated at
-20C for >10 min. RPTEC and HEK293A-5-HT2AR cells were washed in PBS and fixed with 4%
paraformaldehyde (PFA) at RT for 10 min. Fixed cells were washed with PBS three times for 10 min, then
incubated with PBS-0.5% TX100 for permeabilization. RPTEC and HEK293A-5-HT2AR cells were blocked in
10% goat serum (Sigma-Aldrich) at RT for 1 h prior to staining. Cells were then stained using PAB597
(1:10) [35], PAB962 (1:2) or using AB2 (Calbiochem, 1:50) [273] and a secondary anti-mouse Alexa Fluor
polyclonal 488 or 594 antibody (Thermo Fisher Scientific). Cell nuclei were counterstained using DAPI.
The number of infected cells per visual field was assessed by analysis of nuclear VP1 or TAg staining
under a 10X objective using a Nikon Eclipse Ti epifluorescence microscope (Micro Video Instruments,
Inc.). At least 5 visual fields per well were quantitated for triplicate wells for experiments performed at
least 3 times. Percent infection was determined by quantitating the number of TAg positive nuclei
divided by the number of DAPI positive nuclei under a 20X objective. The number of DAPI positive nuclei
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was determined utilizing the Nikon NIS-Elements Basic Research software (Version 4.5). A binary was
generated to quantitate the number of cells per field determined by the number of DAPI positive nuclei
based on threshold fluorescence. The binary controlled for nuclei of equal diameter and circularity to
distinguish between cells in the same field. The average percent infection was then normalized to the
DMSO or siRNA control as indicated.
2.3.9. Flow cytometry to measure viral attachment
SVG-A cells at 100% confluence in 6 well plates (1e6) (Grenier Bio-One) were treated with DMSO
(1:1000) or U0126 (10 m) at 37C for 1 h. Cells were removed from 6 well plates by washing with PBS
and incubating in Cellstripper (Corning). Cells were pelleted at 376 x g at 4C for 5 min and washed with
PBS. Cells were incubated with Alexa-488 labeled JCPyV (JCPyV-488) in PBS (100 l total volume) on ice
for 2 h with agitation every 15 min. Cells were washed, pelleted by centrifugation, and resuspended in
500 l of in PBS. Cells were then analyzed for virus binding using a BD FACSCanto (BD Biosciences)
equipped with a 488 laser excitation line (Benton, Dickinson, and Company). Data were analyzed using
BD FacsDIVA (Benton, Dickinson, and Company) and FlowJo software (Tree Star, Inc.).
2.3.10. Trypan blue quenching assay of viral internalization
SVG-A cells were plated to ~95% confluence in 6 well plates (Grenier Bio-One) and pretreated
with complete media containing either DMSO (1:1000) or U0126 (10 m) at 37C for 1 h. Cells were
removed from plates using Cellstripper (Corning), pelleted at 376 x g at 4C for 5 min and washed with
PBS. Cells were then resuspended with cold phenol-free MEM containing 10% FBS and 1% P/S and
chilled at 4C for 30 min. Cells were pelleted, then incubated with JCPyV-488 at 4C on ice for 1.5 h with
agitation every 15 min to allow for viral attachment. Suspensions were pelleted at 376 x g at 4C for 5
min and washed with PBS. Cell pellets were then resuspended with cold phenol-free medium containing
10% FBS and 1% P/S containing either DMSO (1:1000) or U0126 (10 m). Samples were either fixed
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(attachment) or placed directly into a 37C waterbath for 90 min (entry). At 0 or 90 min post-incubation
at 37C, cells were pelleted at 376 x g at 4C for 5 min and resuspended in 4% PFA on ice for 10 min.
Cells were pelleted, washed, and resuspended in a final volume of 1XPBS or 1XPBS containing Trypan
blue (0.016%). Samples were analyzed using a BD LSRII equipped with a 488 nm laser line. Data were
analyzed using BD FACSDIVA (Benton, Dickinson, and Company) and FlowJo software (Tree Star, Inc.).
Quenched (Trypan blue addition) and non-quenched samples (without Trypan blue) from U0126- and
DMSO-treated samples were assessed by flow cytometry (adapted from [48]) to determine impact of
ERK inhibition on viral attachment (viral binding only) and viral internalization (binding and entry
through 37C incubation). Using the vehicle control as a reference, sample events were gated to remove
cellular debris using FlowJo software. Percent protected fluorescence of averaged FITC readings from
quenched (Trypan blue addition) and non-quenched samples ((quenched sample/non-quenched sample)
x 100 = percent protected fluorescence) were calculated from three independent experiments.
2.3.11. Viral early/late promoter transfections
SVG-A cells were plated to ~60% confluence in 24 well plates (Grenier Bio-One). Cells were pretreated for 4 h with medium containing either DMSO (1:1000) or U0126 (10 M). Cells in medium
without antibiotics were transfected with 1.8 g of either JCPyV-Mad-1 early or JCPyV-Mad-1 late
plasmid DNA containing a firefly luciferase reporter (generously provided by the Atwood lab (Brown
University)) in addition to 0.2 g of a Renilla luciferase control plasmid pRL-TK (Promega) using a 3:1
ratio (Fugene:DNA) and incubated at 37C as previously described [67]. At 4 h post-transfection,
transfection medium was removed and cells were fed with complete media containing vehicle control
DMSO (1:1000) or U0126 (10 M) and incubated at 37C. At 48 h post-transfection, cells were analyzed
for viral promoter activity with a Dual-Luciferase Reporter Assay System (Promega) per manufacturer’s
protocol. Firefly luciferase readings were normalized to the Renilla control (Firefly – Renilla = promoter
activity), performed with triplicate samples from three independent experiments.
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2.3.12. qPCR determination of TAg and VP1 transcript levels
SVG-A and HEK293A-5-HT2AR cells were plated to ~70% confluency in 12 well plates (Greiner BioOne). Cells were transfected with siRNAs specific for ERK1/2 or EGF receptor control (Cell Signaling
Technology) (7.5 pmol final concentration of siRNA per well) using RNAiMax transfection reagent
(Invitrogen) by mixing transfection complexes in serum- and antibiotic-free MEM or DMEM (Corning)
and incubating at RT for 10 min. Complexes were added to cells and incubated at 37°C for 48 h.
Transfection efficiency was monitored using Block-iT Alexa Fluor Red Control oligo (Life Technologies).
At 48 h post-transfection, growth media was removed, cells were washed with PBS and were
subsequently infected with JCPyV at an MOI of 1 FFU/cell in a volume of 350 L, and incubated at 37C
for 1 h. Cells were fed with complete MEM or DMEM and incubated at 37°C for 48 h. At 48 h postinfection, RNA was extracted from each sample with the SingleShot Cell Lysis kit (Bio-Rad) per
manufacturer’s protocol. For each sample collected RNA was converted to cDNA with iScript ReverseTranscription Supermix (Bio-Rad) using 1 g of RNA per reaction. Analysis of viral gene expression was
performed via qPCR using TAg and GAPDH (housekeeping gene) primers as previously described [44]
(IDT). Using Hard-Shell 96-well PCR plates (Bio-Rad), each well was prepared with 150 nM of both
forward and reverse primers (GAPDH and TAg run individually for each sample), 100 ng sample cDNA, 10
L iQ SYBR Green Supermix (Bio-Rad) and nuclease-free water to a total volume of 20 L per well. The
plate was sealed with Microseal ‘B’ seal Seals (Bio-Rad) and centrifuged at 168 x g for 1 min. qPCR
analysis was performed on a Bio-Rad CFX96 Real-Time System, using Bio-Rad CFX Manager software 3.1.
Analysis of gene expression was detected with SYBR green within each sample per running conditions
previously described [44]. Calculation of CT for TAg was determined by (TAg CT – GAPDH CT).
Calculation of CT for ERK siRNA treated samples was determined by (ERK siRNA CT – EGFR siRNA
CT) for TAg. The average fold change of TAg transcript levels between EGFR- and ERK- siRNA treated
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cells was performed using 2-CT of average calculated TAg CT values. Viral gene expression of TAg was
determined by qPCR using triplicate samples from three independent experiments.
2.3.13. Statistical analysis
Student’s t-test (Microsoft Excel) was used to compare means for at least triplicate samples. P
values <0.05 were considered statistically significant in our statistical analyses.
2.4. Results
2.4.1. Inhibition of ERK blocks JCPyV infection in glial cells
To determine whether ERK is necessary for JCPyV infection, SVG-A cells were transfected with
siRNA targeted toward ERK1 and ERK2 to reduce ERK1/2 protein levels in cells (Figure 2.1A) and then
infected with JCPyV or the control SV40 polyomavirus (Figure 2.1B). Cells expressing the ERK1/2 siRNA
demonstrated a 97% decrease in JCPyV infection compared to cells expressing a control siRNA, while no
significant reduction in SV40 infection was observed (Figure 2.1B). These data suggest that ERK is
required for JCPyV infection, yet ERK activity is not required for infection of the closely-related
polyomavirus SV40. To confirm that JCPyV infection of glial cells is dependent on the activation of the
MAPK-ERK, cells were treated with ERK inhibitors PD98059 (2’-Amino-3’-methoxyflavone) and U0126
(1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene), which both bind to MEK1 and MEK2
preventing ERK phosphorylation [274,275]. SVG-A cells treated with PD98059 demonstrated a ~75%
reduction in JCPyV infection in comparison to control DMSO-treated cells (Figure 2.2A). However,
PD98059 had no effect on SV40 infection in SVG-A cells (Figure 2.2B), indicating that the inhibition of
this pathway is specific for JCPyV. Treatment with ERK inhibitor U0126, also reduced JCPyV infection by
~75% (Figure 2.2C) yet had no effect on SV40 infection (Figure 2.2D). The efficacy of the MEK inhibitors
PD98059 and U0126 in SVG-A cells was analyzed through western blot analysis of cellular levels of
phosphorylated ERK (pERK) in comparison to DMSO-treated cells (data not shown). Treatment of cells
with PD98059 decreased levels of phospho-ERK, yet U0126 resulted in a more significant decrease,
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suggesting that U0126 is a more effective inhibitor of ERK phosphorylation in SVG-A cells. Due to these
results, in addition to U0126 being reported as a more potent inhibitor with a greater IC 50 value [275],
subsequent experiments were performed using U0126 at a concentration of 10 μM to effectively inhibit
ERK phosphorylation. The indicated concentrations of inhibitors did not affect cell viability as measured
by MTS assay and flow cytometric analysis of Propidium iodide-stained cells (data not shown).
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Figure 2.1. Gene silencing of ERK reduces JCPyV infection in SVG-A cells.
SVG-A cells were transfected with siRNAs targeted to ERK1/2, a scrambled, or EGFR (CTL) siRNA. At 48 h posttransfection, cells were either (A) harvested for analysis of ERK protein expression or (B) infected. (A) Cell lysates of
siRNA-treated cells were resolved by SDS-PAGE and analyzed via western blot to confirm ERK-specific knockdown
using antibodies specific for tubulin (red) and ERK1/2 (green). Blot is representative of three independent
experiments. (B) SVG-A cells transfected with ERK or control siRNAs were infected with JCPyV (MOI = 0.1 FFU/cell)
or SV40 (MOI = 0.001 FFU/cell). Infected cells were scored by indirect immunofluorescence using a VP1-specific
antibody that recognizes both JCPyV and SV40 VP1. Data represent the percentage of JCPyV or SV40-infected VP1+
cells per visual field normalized to the number of DAPI+ cells per field for five 10x fields of view for triplicate
samples (all samples normalized to EGFR control siRNA-treated cells (100%)). Data are representative of 3
independent experiments. Error bars = SD. Student’s t-test was used to determine statistical significance.
*P,<0.001.
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Figure 2.2. Inhibition of ERK phosphorylation decreases JCPyV infection in glial cells.
SVG-A cells were pre-treated with the MEK inhibitor (A, B) PD98059 or (C, D) U0126 at the indicated
concentrations or DMSO at an equivalent volume (of maximum inhibitor concentration) then infected with (A, C)
JCPyV (MOI = 0.1 FFU/cell) or (B, D) SV40 (MOI = 0.001 FFU/cell) at 37°C for 1 h. Cells were incubated in media
containing inhibitors at indicated concentrations for 72 h then fixed and stained by indirect immunofluorescence
using a VP1-specific antibody that recognizes both JCPyV and SV40 VP1. Infectivity was scored by quantitating
nuclear VP1 expression. Data represent the average number of infected cells per visual field for five 10x fields of
view for triplicate samples. Data are representative of 3 independent experiments. Error bars = SD. Student’s t-test
was used to determine statistical significance. *P,<0.05.

2.4.2. JCPyV induces multiphasic ERK activation upon infection
JCPyV infection has been previously shown to induce ERK phosphorylation as early as 15 min
post-infection, with decreasing activation through 9 h post-infection [46], suggesting that
phosphorylation of ERK is required for viral entry and trafficking [46]. However, ERK activation has not
been characterized throughout the JCPyV life cycle. To determine the timing of ERK activation following
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JCPyV challenge, SVG-A cells were infected with JCPyV or mock infected, and cells were harvested at
selected time points and analyzed for ERK phosphorylation by quantitative western blot analysis (Figure
2.3A). A rapid ERK phosphorylation was induced within 10 mins following JCPyV challenge and activation
was sustained in a multiphasic pattern for the first ~6-12 h in comparison to mock-infected cells.
However, the phosphorylated ERK signal waned after 12 h with only a minor increase in the phosphoERK signal at 72 h post-infection in comparison to mock-infected cells (Figure 2.3A). These data suggest
that ERK is activated early during infection, which corroborates previously published findings [46], and
suggests that the rapid ERK activation is not sustained for later steps in the viral life cycle.
To initially characterize how ERK activation (Figure 2.3A) or inhibition (Figure 2.1 and 2.2)
impacts the JCPyV life cycle, SVG-A cells were treated with the ERK inhibitor U0126 under various
treatment regimens (Figure 2.3B). As demonstrated in Figure 2.2, ERK inhibition led to a ~75% decrease
when cells were pre-treated with the U0126 for 1 h prior to infection and the inhibitor was added back
to the media for the duration of the infection (Figure 2.2 and 2.3). In order to determine how ERK
inhibition impacts the JCPyV life cycle, SVG-A cells were pre-treated with U0126 and subsequently
incubated with treated media for the first 1-4 h following infection, which resulted in a ~40% decrease in
infection (Figure 2.3B). This treatment is consistent with the time frame in which the most robust ERK
phosphorylation is noted (0-2 h pi), leading to the hypothesis that ERK activation affects the initial
events in the viral life cycle including attachment and entry [48].
2.4.3. Inhibition of ERK does not affect JCPyV attachment
JCPyV-induced ERK activation is coincident with the timing of viral attachment and entry (Figure
2.3) [46,48]. Further, ligand binding to the 5-HT2Rs, which are required for JCPyV entry, can activate the
MAPK-ERK pathway, which regulates receptor cell-surface expression, endocytosis, and activation of
other signaling pathways [276]. Therefore, the effect of ERK inhibition on viral attachment to host cells
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was analyzed. SVG-A cells were pre-treated with U0126 or DMSO then incubated with Alexa-488-labeled
JCPyV (JCPyV-488) virions on ice to allow for viral attachment (Figure 2.4), and JCPyV-488 binding to
SVG-A cells was subsequently measured by flow cytometry. Treatment of cells with U0126 had no effect
on viral attachment in comparison to DMSO-treated SVG-A cells, suggesting that ERK inhibition does not
affect virus binding to the cell surface.
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Figure 2.3. JCPyV induces multiphasic ERK activation upon infection.
(A) SVG-A cells were infected with JCPyV (MOI = 1 FFU/cell) for the specified duration and were analyzed via
western blot using antibodies specific for phosphorylated ERK (pERK) and total ERK (protein control). The
percentage of pERK was determined using phosphorylated ERK and total ERK band intensities ([pERK/pERK + total
ERK] * 100). The percentage of pERK for JCPyV infected samples was normalized to mock at each time point (mock
= 100%, dashed line). Percentages of phosphorylated ERK for each timepoint were plotted via box-and-whisker
plot and are representative of three independent experiments. (B) SVG-A cells were either pre-treated (PT) for 1 h
prior to JCPyV infection with U0126 (10 µM) or DMSO (1:1000), or incubated in complete media. Cells were then
infected with JCPyV (MOI = 0.1 FFU/cell) at 4°C for 1 h. Following infection, cells were washed with media then
incubated in media with inhibitors for the indicated timepoints. At the specified timepoint, medium was removed,
cells were washed, and complete media was added and cells were incubated at 37°C for 72 h. Cells were fixed and
stained by indirect immunofluorescence using a VP1-specific antibody, and infectivity was scored by quantitating
nuclear VP1 expression. Data are representative of the average number of infected cells per visual field for five 20x
fields of view for triplicate samples. Data are representative of three independent experiments. Error bars = SD.
Student’s t-test was used to determine statistical significance. *P,<0.05.
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Figure 2.4. JCPyV attachment to SVG-A cells is not altered by ERK inhibition.
SVG-A cells in 6 well plates were treated with U0126 (10 M) or DMSO (1:1000) at 37°C for 1 h, then washed with
PBS, and removed from plates using Cellstripper. Cells were washed and incubated with JCPyV-488 on ice for 2 h,
washed with PBS, and binding was analyzed by flow cytometry. Histograms represent the fluorescence intensity of
JCPyV-488 for DMSO-(blue) and U0126-(dashed) treated cells for 10,000 events. Shaded histogram represents cells
that were not incubated with JCPyV (PBS alone). Data are representative of >3 independent experiments.

2.4.4. JCPyV internalization is not affected by ERK inhibition
JCPyV induces ERK activation within 10-15 min of viral infection (Figure 2.3) [46], a time
consistent with viral entry [48]. To determine if ERK activation impacts virus entry, a trypan blue (TB)
quenching assay was utilized to measure viral internalization by flow cytometry [48] (Figure 2.5). In
brief, trypan blue quenches Alexa Fluor-488 fluorescence of plasma membrane-associated labeled virus,
but internalized fluorescently-labeled virus is protected from TB treatment. SVG-A cells were pretreated with DMSO or U0126, incubated with JCPyV-488 on ice at 4C to allow for viral attachment for
90 min, then either fixed or incubated at 37°C for an additional 90 min to allow for entry. Fixed samples
were then treated with or without TB (Figure 2.5A). Trypan blue treatment resulted in ~1-log decrease in
JCPyV-488 fluorescence of attached virus as measured by flow cytometry. Additionally, an increase in
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protected fluorescence in samples incubated at 37°C was observed, indicating that the virus has
internalized at 90 min post-infection and is protected from TB treatment (Figure 2.5A). The extent of
protected fluorescence is consistent with published results of JCPyV entry analyzed via a confocal-based
TB assay [48]. Quantitative analysis of flow cytometry results demonstrated that treatment of cells with
U0126 had no effect on virus attachment or entry as assessed from equivalent levels of virus binding
and entry in U0126- and DMSO-treated cells (Figure 2.5B). Taken together, these data indicate that ERK
inhibition does not affect JCPyV attachment or entry.
2.4.5. ERK inhibition affects the JCPyV infectious cycle at a post-trafficking step
To define whether entry and trafficking of JCPyV are impacted by ERK inhibition, SVG-A cells
were pre-treated with U0126 or DMSO and then transiently transfected with an infectious clone of
JCPyV or SV40 to bypass attachment to viral receptors, endocytosis, and trafficking through the
endocytic compartment (Figure 2.6). Cells were fixed and stained for VP1 expression at days 4 and 7
following transfection. JCPyV VP1 expression was decreased in U0126-treated cells in comparison to
DMSO-treated cells (Figure 2.6A), yet SV40 VP1 expression was not altered in response to U0126
treatment (Figure 2.6B). These data indicate that inhibition of ERK blocks a step in the JCPyV life cycle
that occurs after trafficking.
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Figure 2.5. Entry of JCPyV does not require ERK activation.
(A) SVG-A cells treated with either U0126 (10 M) or DMSO (1:1000) were incubated with JCPyV-488 on ice at 4°C
to promote viral attachment. Cells were fixed (attachment) or transferred to 37°C for 90 min to promote viral
internalization (entry). Quenched samples (trypan blue (TB) treated, blue) and unquenched samples (gray) were
then assayed by flow cytometry. Samples were gated to remove cellular debris. Histograms are representative of
the mean fluorescence intensity from one replicate for each treatment (n = 10,000 events). (B) The percent
protected fluorescence was calculated by (% protected fluorescence = ((FITC +TB /FITC -TB)*100) for three
individual experiments (each with 10,000 events). Data are the average of three independent experiments (n =
30,000 events). Error bars = SD.
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Figure 2.6. ERK inhibition impacts a post-entry step in infection.
SVG-A cells were treated with either U0126 (10 M) or DMSO (1:1000) for 1 h then transfected with an infectious
clone of (A) JCPyV or (B) SV40. At either 4 or 7 days post-transfection, cells were fixed and stained using a VP1specific antibody and analyzed by indirect immunofluorescence for infectivity. Data are representative of the
number of infected cells per visual field for five 10x fields of view for triplicate samples. Data are representative of
three independent experiments. Error bars = SD. *P,<0.05.

2.4.6. ERK inhibition decreases JCPyV early and late promoter activity
Activation of the MAPK-ERK pathway can lead to phosphorylation of ERK and its subsequent
translocation to the nucleus where it can activate transcription factors, including transcription factors
known to be involved in JCPyV infection such as NFAT4 [67] and SMADS 2 and 4 [64]. Polyomaviruses
have a bidirectional transcription program, in which the viral early genes are transcribed first including
large T-antigen, followed by genome replication, then transcription of the late viral genes that encode
for the structural capsid proteins including VP1 [8,12]. To analyze potential effects of ERK inhibition on
viral transcription, viral promoter activity was measured in SVG-A cells treated with the ERK inhibitor
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U0126. Cells were treated with DMSO or U0126 then transfected with an early- or late- viral promoter
construct containing a luciferase reporter [67], and luciferase production was measured at 48 h posttransfection (Figure 2.7). ERK inhibition resulted in a significant decrease in both early and late promoter
activities as measured by luciferase production, indicating that inhibition of ERK reduces viral promoter
activity and may therefore directly impact the transcription of early and late viral genes in SVG-A cells.
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Figure 2.7. ERK inhibition blocks JCPyV promoter activity.
SVG-A cells were pre-treated with U0126 (10 M) or DMSO (1:1000) for 4 h and subsequently transfected with
luciferase expressing plasmids containing the JCPyV Mad-1 prototype strain (A) early or (B) late promoters and a TK
renilla luciferase plasmid as a control. At 4 h post-transfection, media containing U0126 (10 M) or DMSO (1:1000)
was added back to cells. At 48 h post-transfection, cells were assayed for luciferase production, indicative of viral
promoter activity, by luminometry. Data represent the average relative luciferase units produced from triplicate
samples normalized to TK renilla luciferase expression. These data are representative of three independent
experiments. Error bars = SD. *P,<0.05.
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2.4.7. Inhibition of ERK blocks JCPyV infection in kidney cells
To determine whether ERK is required for JCPyV infection of kidney cells, primary renal proximal
tubule epithelial cells (RPTECs) and HEK293A cells stably expressing 5-HT2AR -YFP (HEK293A-5-HT2AR)
were analyzed. HEK293A cells are poorly permissive for JCPyV infection unless transfected with the 5HT2Rs [41]. RPTECs and HEK293A-5-HT2AR cells were pre-treated with either DMSO or U0126 for 1 h then
infected with JCPyV (Figure 2.8A and 2.8B) or SV40 (Figure 2.8C) then incubated with either DMSO or
U0126 for 48 h. HEK293A-5-HT2AR cells treated with U0126 demonstrated a ~50% decrease in JCPyV
infection compared to cells treated with DMSO, suggesting that ERK is required for JCPyV infection in
kidney cells (Figure 2.8B) but not required for SV40 infection (Figure 2.8C). To ensure that the
transformation of the HEK293A-5-HT2AR cells with the adenovirus E1 gene [277] did not influence the
impact of ERK inhibition on JCPyV infectivity, primary RPTECs were infected with JCPyV in the presence
of U0126 (as described above) (Figure 2.8A). Inhibition of ERK in RPTECs resulted in a ~40% decrease in
JCPyV infectivity, suggesting that ERK activity is also required for JCPyV infection in primary kidney cell
lines. SV40 does not productively infect RPTECs [278] and thus could not be utilized as a control.
Together, these data suggest that the MAPK-ERK cascade is required for JCPyV infection of both kidney
and glial cell types.
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Figure 2.8. Inhibition of ERK phosphorylation decreases JCPyV infection in kidney cells.
(A) RPTEC and (B, C) HEK293A-5-HT2AR cells were pre-treated with U0126 (10 M) or DMSO (1:1000) at 37°C for 1
h, then infected with (A, B) JCPyV (MOI = 0.5 FFU/cell) or (C) SV40 (MOI = 0.001 FFU/cell) at 37°C for 1 h. Cells were
incubated in media containing inhibitors at 37°C for 48 h then fixed and stained by indirect immunofluorescence
using JCPyV- or SV40-T-antigen specific antibodies. Infectivity was scored by quantitating nuclear T-antigen
expression. Data represent the percentage of JCPyV- or SV40-infected cells per visual field normalized to the
number of DAPI+ cells per field for five 20x fields of view for triplicate samples from three independent
experiments. Samples were normalized to the DMSO-treated control cells (100%). Error bars = SD. Student’s t-test
was used to determine statistical significance. *P,<0.05.
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2.4.8. T-antigen expression is reduced in kidney and glial cell types when ERK is inhibited
To determine whether the activation of the MAPK-ERK pathway is necessary for expression of
the viral early gene T-antigen, SVG-A cells were transfected with a siRNA to reduce ERK1/2 protein levels
and then infected with JCPyV and T-antigen production was measured by indirect immunofluorescence
(Figure 2.9A). Cells expressing an ERK1/2 siRNA demonstrated an 85% decrease in T-antigen expression
compared to cells expressing a control siRNA. SVG-A cells are transformed with an origin defective SV40
T-antigen [267], and thus SV40 T-antigen expression cannot be measured in SVG-A cells as a control. To
ensure that the effect of ERK inhibition was not affected by T-antigen transformation of the SVG-A cells,
HEK293A-5-HT2AR cells were also treated with the ERK1/2 siRNA and infected with JCPyV or SV40 as a
control (Figure 2.9B and 2.9C). JCPyV T-antigen expression was reduced by 79% in HEK293A-5-HT2AR
cells treated with the ERK1/2 siRNA (Figure 2.9B) while SV40 T-antigen expression was unaffected by
ERK inhibition (Figure 2.9C). Additionally, RPTECs treated with the ERK inhibitor U0126 demonstrated a
significant decrease in T-antigen production as measured by indirect immunofluorescence (Figure 2.8A).
These data suggest that inhibition of ERK activation impacts the production of T-antigen and possibly the
initiation of viral JCPyV transcription.
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Figure 2.9. ERK activation is required for viral early gene expression.
(A) SVG-A and (B, C) HEK293A-5-HT2AR cells transfected with ERK1/2 or control siRNAs were infected with (A, B)
JCPyV (MOI = 1 FFU/cell) or (C) SV40 (MOI = 0.001 FFU/cell). Infected cells were scored by indirect
immunofluorescence using JCPyV- or SV40-T-antigen specific antibodies. Data represent the percentage of JCPyVor SV40-infected cells per visual field normalized to the number of DAPI+ cells per field for five 10x fields of view
for triplicate samples (all samples normalized to EGFR control siRNA-treated cells (100%)). Data are representative
of three independent experiments. Error bars = SD. Student’s t-test was used to determine statistical significance.
*P,<0.001.

2.4.9. ERK inhibition decreases JCPyV viral gene expression
ERK inhibition decreased both the activity of viral early and late promoters (Figure 2.7) and the
production of the viral early gene product T-antigen (Figure 2.8, 2.9), indicating that activation of the
MAPK-ERK pathway may impact JCPyV transcription. Further, phosphorylated ERK can initiate
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transcription and subsequent gene expression [72]. As successful JCPyV infection is necessitated by ERK
activity, it is possible that JCPyV utilization of the MAPK-ERK pathway provides a means to reprogram
host cell transcription patterns for viral transcription. To determine if ERK activity plays a direct role in
promoting viral gene expression, SVG-A and HEK293A-5-HT2AR cells were treated with ERK1/2 siRNA or
control siRNA then infected with JCPyV for 48 h. RNA was extracted from cells, converted to cDNA, and
analyzed by qPCR to determine relative gene expression of TAg (Figure 2.10). ERK silencing in SVG-A and
HEK293A-5-HT2AR cells resulted in a 74- and 51-fold decrease in viral gene expression respectively,
compared to control siRNA-treated cells. These data demonstrate that ERK activation is a positive
regulator of JCPyV gene expression in both kidney and glial cell types.
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Figure 2.10. JCPyV T-antigen transcript levels are reduced by ERK inhibition.
SVG-A and HEK293A-5-HT2AR cells were treated with either an ERK1/2 or EGFR (CTL) siRNA for 48 h then infected
with JCPyV (MOI = 1 FFU/cell), fed with appropriate media, and incubated at 37°C for 48 h. Cells were harvested
and cDNA was prepared from individual triplicate samples, and each sample was analyzed by qPCR to determine
viral gene expression. The average fold change in TAg expression in ERK1/2 siRNA-treated cells was calculated per
2^-[(ERK siRNA TAg CT – ERK siRNA GAPDH CT) – (EGFR siRNA TAg CT – EGFR GAPDH CT)]. Data are representative
of the average fold change calculated from triplicate samples from three independent experiments. Error bars
represent standard deviation between three independent experiments.
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2.5. Discussion
JCPyV infection was previously shown to require the activity of tyrosine kinases [46] and to induce
the activation of MAPK-ERK at times consistent with virus entry and trafficking [46,48]. Our results
corroborated previously published findings and further revealed that while JCPyV infection results in a
robust ERK activation immediately upon infection, there is a multiphasic pattern of ERK phosphorylation
throughout the viral life cycle (Figure 3). However, whether the MAPK-ERK signaling pathway was
necessary for JCPyV infection and how the activation of these signaling events affected JCPyV infection
remained uncharacterized. Herein, we demonstrate that JCPyV infection is dependent upon ERK
activation as siRNA directed toward ERK1/2 significantly reduces JCPyV infection (Figure 2.1). Further,
inhibition of MEK, which blocks phosphorylation of ERK, significantly reduces JCPyV infection (Figure
2.2), indicating that the MAPK-ERK pathway is required for JCPyV infection. While ERK activation is
induced immediately upon viral infection and inhibition of ERK within the first four hours of viral
infection resulted in a significant decrease in infection (Figure 2.3), inhibition of ERK activation had no
effect on viral attachment, entry, or trafficking (Figure 2.4, 2.5, and 2.6). Interestingly, ERK inhibition
resulted in significantly reduced viral promoter activity (Figure 2.7) and expression of the viral early gene
T-antigen in both kidney and glial cells (Figure 2.8, 2.9, and 2.10), indicating that ERK is required for
JCPyV transcription. These findings indicate that JCPyV induces ERK activation upon viral infection to
influence downstream steps in the viral life cycle.
Currently, the mechanisms by which JCPyV alters host cell signaling pathways in order to
promote viral pathogenesis are poorly understood. We have determined that the activation of ERK plays
a critical role in regulating JCPyV gene transcription (Figure 2.10), potentially through the activation of
crucial viral transcription targets necessary for infection. Viral TAg expression was significantly
decreased in both SVG-A and HEK293A-5-HT2AR cells treated with an ERK siRNA (Figure 2.9) and in SVG-A
(data not shown), HEK293A-5-HT2AR, and RPTEC cells treated with an ERK inhibitor (Figure 2.8). These
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changes in early gene expression, suggest that ERK is a positive regulator of JCPyV transcription in both
kidney and glial cell types. MAPK-ERK signaling controls the activation of transcription factors necessary
for cellular growth, proliferation, and cell death [279]; it is seemingly this functionality that is usurped by
JCPyV during infection to promote viral propagation. JCPyV infection was previously shown to be
enhanced in progenitor-derived astrocytes (PDAs) stimulated with TGF-β1 through a mechanism
involving the upregulation of MAPK-ERK activity [64]. The TGF-β1-stimulated PDAs also had increased
expression of the DNA-binding proteins, SMADS 2 and 4 [64]. Our data build upon these findings by
showing that the ERK activation in SVG-A cells, the model cell line for JCPyV studies, is necessary for
JCPyV infection and expression of key viral genes independent of TGF-β1 stimulation. Furthermore,
while SVG-A cells are transformed with large T-antigen, HEK293A-5-HT2AR cells are stably transformed
with the adenovirus E1 gene [280] and RPTECs are a non-transformed primary cell type (ATCC),
suggesting that the expression of the SV40 T-antigen does not impact the effect of ERK inhibition on
JCPyV infection. Future studies will focus on defining downstream targets of JCPyV-induced MAPK
activation such as the transcription factor NFAT4, which is crucial for JCPyV infection [67] and can be
activated through ERK activity [281].
ERK activation is initiated early during JCPyV infection (Figure 2.3) [46], consistent with viral
attachment, entry, and trafficking [48]. The 5-HT2Rs are required for JCPyV entry [41], and ligandactivation of 5-HT2Rs and subsequent endocytosis can activate the MAPK-ERK pathway [282], suggesting
that ERK activation may be linked to viral association with the 5-HT2Rs. The 5-HT2Rs induce MAPK-ERK
signaling through the action of tyrosine kinases which activate protein kinase C (PKC) [262,283,284],
stimulating GTPase Ras binding to the serine/threonine kinase Raf and subsequent MEK activation and
ERK phosphorylation [261,285,286]. Our data demonstrate that JCPyV infection activates the MAPK-ERK
signaling pathway through a mechanism involving MEK and ERK. Additionally, an inhibitor of Raf, the
kinase directly upstream of MEK, significantly reduces JCPyV infection (data not shown), suggesting that
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JCPyV activates ERK through Raf and MEK. The endocytosis of 5-HT2Rs can lead to the activation of the
MAPK-ERK pathway [287,288], and interestingly, ERK is activated almost immediately following JCPyV
challenge (Figure 2.3) [46], suggesting that signaling through MAPK-ERK may be activated upon
engagement of viral receptors or during cellular entry [48]. However, future studies are required to
determine the mechanisms by which JCPyV activates ERK. Additionally, the role of attachment receptor
motif LSTc in JCPyV-mediated ERK activation cannot be discounted as sialic-acid-containing receptors
such as gangliosides can also lead to the activation of the MAPK pathway and activation of downstream
transcription factors like NF-κB [264,289,290]. Interestingly, JCPyV has been demonstrated to bind to
multiple sialylated gangliosides including GM1 and GM2, albeit with reduced affinity in comparison to
LSTc, yet gangliosides cannot support JCPyV infection [36]. Thus, binding to sialic acid receptors could
also activate the MAPK pathway, especially given that MPyV-ganglioside interactions activates MAPK
[264]. However, inhibition of ERK does not alter virus binding or entry (Figure 2.4 and 2.5), suggesting
that while the signal is activated during the initial steps of the virus life cycle (Figure 2.3), signaling
through this pathway is not required for attachment or entry.
Several members of the Polyomaviridae have been shown to both directly or indirectly activate
MAPK-ERK, yet the downstream consequences of this activation differs among the polyomaviruses.
MPyV activates the MAPK-ERK pathway [60,264], but MAPK pathway activation is not required for
infection [264]. BKPyV does not directly activate ERK [147,265], yet conditions that activate the MAPKERK pathway enhance BKPyV replication [147]. However, BK polyomavirus infection does activate the
AKT-mammalian target of rapamycin (mTOR)-S6 kinase upon infection, likely through receptor
interactions, and this signaling pathway enhances BKPyV replication [265]. Given that the
phosphatidylinositol 3-kinase PI3K-mTORC1 pathway can cross-activate or cross-inhibit the ERK pathway
[291], it is possible that while BKPyV does not directly activate MAPK-ERK, ERK activation does enhance
the mTORC1 signaling pathway thereby contributing to increased BKPyV replication [265]. Activation of
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mTORC1 and MAPK pathways also regulates translation [291], and therefore, it is possible that inhibition
of these pathways could limit translation of transcription factors necessary for viral transcription.
Furthermore, SV40 polyomavirus has not been reported to directly activate the MAPK-ERK pathway
[60], but rather activates a MAPK-ERK-independent signaling pathway that induces Ca2+ mobilization and
kinase activity of PKC, without downstream activation of Raf or MAPK-ERK [266]. Interestingly,
polyomavirus T-antigen proteins, including those of JCPyV, MPyV, and SV40, interact with the MAPK
pathway through binding to PP2A. The small T-antigen protein of JCPyV binds to PP2A and influences
cell cycle progression and viral replication [59]. However, as ERK is activated immediately upon JCPyV
infection (Figure 2.3) [46], it suggests that activation of this signaling cascade precedes T-antigen
expression.
Therefore, it remains possible that JCPyV T-antigen binding to PP2A serves a regulatory role to
halt transcription at a critical point in T-antigen production. Thus, while other polyomaviruses can
differentially activate MAPK signaling cascade, it is dispensable for the infectious life cycle of SV40 and
MPyV, yet BKPyV is enhanced by ERK activation and JCPyV-induced MAPK activation is necessary for
infection specifically by promoting viral transcription. Moreover, as other polyomaviruses have
demonstrated the ability to induce biphasic signaling of particular pathways [147,264,292], JCPyV may
act to alter normal ERK phosphorylation patterns to promote infection. Analysis of ERK phosphorylation
patterns following viral challenge indicate that there is a rapid and robust activation of ERK immediately
following infection at times consistent with viral attachment, entry, and trafficking (Figure 2.3) [34,48].
Our results expand upon previously published findings [46], demonstrating that ERK phosphorylation
continues through 12 hpi in a multiphasic pattern that diminishes and eventually stabilizes over the
course of infection with a slight increase in ERK phosphorylation at 72 hpi (Figure 2.3). These data may
suggest that JCPyV-induced ERK activation is multiphasic in nature and that ERK is required early in the
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infectious process to accumulate the transcription factors necessary for viral transcription and
replication.
A number of other viruses activate the MAPK-ERK signal transduction pathway including
hepatitis C virus, HIV-1, influenza virus (IAV), SARS corona virus (SARS-CoV), Kaposi's sarcoma-associated
herpesvirus (KSHV), and Epstein-Barr virus (EBV), which co-opt various cellular functions of MAPK
pathway for infectivity and replication [73,237]. For example, HIV-1 activates the MAPK pathway
through GP120 binding to the CD4 and CXCR4 receptors leading to the activation of ERK and cytoskeletal
rearrangements necessary for viral replication and infection [293]. Coxsackie virus B3 (CVB3) activates
the MAPK pathway resulting in decreased coxsackie virus and adenovirus receptor (CAR) binding but
reactivation later in the viral replication cycle leads to caspase 3 induction and cell lysis. Moreover,
CVB3-induced cell lysis is blocked by the MEK inhibitor, U0126, resulting in a reduction in virus release
[294]. SARS-CoV and mouse hepatitis virus (MHV) also activate the MAPK-ERK pathway, and inhibition of
ERK leads to a reduction of viral progeny, thereby limiting viral spread [295-297].Therefore, viruses
usurp the MAPK-ERK signaling pathway to drive various aspects of the virus life cycle through unique
mechanisms that ultimately impact infection and pathogenesis. While the impact of cellular
reprogramming by the MAPK pathway during JCPyV infection affects transcriptional regulation,
additional effects on the infectious life cycle should be further elucidated given the range of effects
discovered with other viruses.
Taken together, the data presented herein demonstrate that JCPyV activates the MAPK-ERK
pathway in order to promote viral transcription. ERK is phosphorylated almost immediately following
JCPyV infection, yet inhibition of ERK activation through inhibitors and gene silencing, abolishes JCPyV
infection. Inhibition of ERK does not alter virus attachment, entry, or potential trafficking of the virus.
However, viral transcription is significantly decreased when ERK is inhibited as demonstrated through
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reduced promoter activity and a significant reduction in the early gene T-antigen production. Infection
with the related polyomavirus SV40 was unaffected by the inhibition of ERK, demonstrating that the
activation of the MAPK-ERK pathway in glial and kidney cells was specific for JCPyV. Future studies will
focus on defining the mechanism by which JCPyV activates the MAPK-ERK pathway and the downstream
consequences of ERK activation on cellular transcriptional control.
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CHAPTER 3
JCPYV-INDUCED MAPK SIGNALING ACTIVATES TRANSCRIPTION FACTORS TO DRIVE INFECTION
The work presented in this chapter has been submitted for consideration for publication in International
Journal of Molecular Sciences on 06 Aug 2019.
3.1. Chapter Summary
JC polyomavirus (JCPyV), a ubiquitous human pathogen, is the etiological agent of the fatal
neurodegenerative disease progressive multifocal leukoencephalopathy (PML). Like most viruses, JCPyV
infection requires the activation of host-cell signaling pathways in order to promote viral replication
processes. Previous works have established the necessity of the extracellular signal-regulated kinase
(ERK), the terminal core kinase of the mitogen-activated protein kinase (MAPK) cascade (MAPK-ERK) for
facilitating transcription of the JCPyV genome. However, the underlying mechanisms by which the
MAPK-ERK pathway becomes activated and induces viral transcription are poorly understood.
Treatment of cells with siRNAs specific for MAP kinase kinase (MEK) and Raf, target proteins in the
MAPK-ERK cascade, significantly reduced JCPyV infection. The MEK, the dual-specificity kinase
responsible for the phosphorylation of ERK, is phosphorylated at times congruent with early events in
the virus infectious cycle. Moreover, a MAPK-specific signaling array revealed that transcription factors
downstream of the MAPK-ERK cascade, including cMyc and SMAD4, are upregulated within infected
cells and shuttle to the nucleus during infection. These findings suggest that JCPyV induction of the
MAPK-ERK pathway leads to the recruitment and activation of transcription factors necessary for viral
transcription. This study characterizes the role of the MAPK-ERK cascade during JCPyV infection and the
downstream signaling consequences, illuminating kinases as potential therapeutic targets for viral
infection.
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3.2. Introduction

JC polyomavirus is a common human pathogen that can cause a fatal neurological disease in
individuals who are immunocompromised [10]. JCPyV infects between 50-80% of the population and
causes a persistent asymptomatic kidney infection in healthy individuals [15,16]. In individuals who are
severely immunosuppressed, often in association with HIV-1 infections or prolonged
immunomodulatory therapy treatment for multiple sclerosis (MS), JCPyV reactivates and spreads to the
central nervous system (CNS) [38,298,299]. Within the CNS, JCPyV infects glial cells, astrocytes and
oligodendrocytes, responsible for production of myelin and myelination support [300,301]. Viral
cytolytic destruction of the myelin-producing oligodendrocytes results in the loss of myelin within the
CNS resulting in the development of the fatal neurodegenerative disease progressive multifocal
leukoencephalopathy [12,302]. The formation of lesions within the brain is the hallmark of PML onset
and symptoms of the disease include hemiparalysis and altered cognitive functioning [303]. Currently,
there are limited therapies available for the treatment or prevention of PML, yielding a high mortality
rate for this devastating disease [8].

JCPyV is a small, non-enveloped virus with a double-stranded DNA genome encased within a
proteinaceous capsid [8]. Infection of host cells is initiated by JCPyV attachment to the terminal 2,6linked sialic acid on lactoseries tetrasaccharide c (LSTc) via the exterior viral capsid protein, viral protein
1 (VP1) [8,34-36]. This attachment receptor however, only facilitates viral binding to the host cell; JCPyV
requires the 5-hydroxytryptamine 2 (5-HT2) family of receptors for entry into the cell [39,41]. Viral
internalization into the host-cell is facilitated by clathrin-mediated endocytosis machinery, including the
scaffolding protein -arrestin [42,304]. Upon the completion of endocytosis, the virus traffics through
the endocytic compartment to the endoplasmic reticulum (ER), where the virion capsid becomes
partially uncoated [51]. JCPyV eventually translocates into the host-cell nucleus where the DNA
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replication machinery is hijacked by the virus to facilitate transcription and replication of the viral
genome in a temporal fashion [128]. The viral early genes, comprised of the T-antigens (TAg), drive the
replicative process to produce the capsid components, late viral proteins VP1, VP2, and VP3 [8,128]. This
temporal regulation pattern of the viral genome is common to nearly all DNA viruses, due in large part
to the fact that most DNA viruses rely almost completely on hijacking the requisite machineries from the
host cell in order to replicate [305].

An essential part of host-cell dysregulation during viral infection occurs through the
manipulation of cellular signaling mechanisms, the cascades that facilitate intracellular and extracellular
communication. JCPyV activates the extracellular-signal regulated kinase (ERK) component of the
mitogen-activated protein kinase (MAPK-ERK) cascade upon infection, which is required for viral
transcription and infection [64,132]. MAPK-ERK functions to transmit external mitogenic signals inward,
to generate the appropriate cellular responses such as: cellular growth, differentiation, or cellular
survival [71,72]. The MAPK-ERK pathway proceeds through a series of sequential phosphorylation
events of the three main kinases that comprise the MAPK-ERK pathway: Raf, MAP kinase kinase
(MEK1/2), and ERK1/2 [71,306]. Initially, the pathway is activated upon ligand binding and receptor
tyrosine kinases (RTKs) or G proteins, which then lead to activation of the small GTPase Ras at the
plasma membrane [307]. Ras binds to the serine/threonine kinase Raf, which phosphorylates MEK1/2
[71,72]. The dual specificity kinases MEK1/2 then phosphorylate ERK1/2 [71,72]. As the terminal kinase
in the MAPK-ERK cascade, ERK is a dynamic and potent signaling molecule that activates downstream
signaling targets, becomes dephosphorylated by protein phosphatases, activates cytoplasmic targets or
translocates to the nucleus to regulate transcription factors that function in cell proliferation,
differentiation, and cell death [263,308].

68

Activated ERK is linked to over 200 known cellular substrates located in both the cytoplasm and
nucleus including MAPK-associated protein kinases (MAPKAPKs), other kinases, and transcription factors
(TFs) that facilitate the transmission of incoming mitogenic signals [71,80,306]. The majority of these
downstream effectors facilitate the transcription and translation of the host-cell gene products
necessary for an appropriate response to the initial stimulus. In particular, transcription factors like
SMAD4, cMyc, cJun, cFos (AP-1) and others, are the predominant TF targets of pERK, eliciting a real-time
cellular response to the incoming stimulus. Interestingly, many DNA viruses that rely on hijacking these
cellular replication machineries, specifically target the MAPK-ERK signaling cascade during the infectious
process due the dynamic influence of this cascade over cellular fate. During infection, JCPyV relies on
usurping host-cell transcription factors including NFAT, NF-kB, SMADs, Sp1, cJun, and cMyc
[64,67,69,136,309-311], which are downstream of the MAPK-ERK signaling pathway, to promote
infection, suggesting that JCPyV might reprogram host-cell transcriptional machinery through activation
of the MAPK-ERK pathway. However, the signaling mechanism(s) that facilitate JCPyV-induced activation
of ERK and whether activation of the MAPK-ERK pathway influences the expression of transcription
factors necessary for JCPyV infection are currently unclear.

The objective of this study was to determine if JCPyV drives the activation of the canonical
MAPK-ERK signaling pathway to promote infection and to determine how host-cell TFs respond to ERK
activation during infection. At timepoints congruent with viral entry, JCPyV infection induces an
upregulation in MEK phosphorylation suggesting that ERK activation occurs through JCPyV-induced
activation of MEK. Moreover, key components of the MAPK-ERK cascade, Raf and MEK are required for
JCPyV infection as cells treated with Raf- and MEK-specific siRNAs demonstrated a significant reduction
in viral infection. These findings suggest that JCPyV infection induces the canonical MAPK-ERK cascade in
order to promote infection. Downstream TF targets of both the MAPK-ERK pathway and of JCPyV
infection such as SMAD4 and cMyc localize predominantly in the host-cell nucleus at timepoints
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associated with viral genome transcription. These data suggest that JCPyV infection induces the
recruitment and activation of MAPK-ERK-associated TFs to promote viral gene transcription and
successful viral infection. Together, these findings suggest that JCPyV infection activates the MAPK-ERK
pathway to promote viral infection through MAPK-ERK activation of downstream transcription factors
necessary for viral transcription.
3.3. Materials and Methods
3.3.1. Cell types, virus strains, reagents and antibodies

SVG-A cells [267] were cultured in Minimum Essential Medium (MEM) (Corning) containing 10%
fetal bovine serum (FBS), 1% penicillin/streptomycin (P/S) (Mediatech, Inc.) and 0.2% Plasmocin
prophylactic (Invivogen) (cMEM). Cells were grown in a humidified incubator at 37°C with 5% CO2. SVG-A
cells were generously provided by the Atwood laboratory (Brown University) and authenticated by
ATCC. JCPyV strain Mad-1/SVEΔ (provided from the Atwood laboratory (Brown University)) was purified
as described [48] and used for infectivity experiments as indicated. The MEK chemical inhibitor U0126
(Cell Signaling Technology) was used reconstituted in DMSO and was used at the indicated
concentration of 10 M for 48 h. DMSO served as a volume-specific vehicle control.

Antibodies used for detection of viral proteins include PAB597 (provided by Ed Harlow) and PAB962
(provided by the Tevethia laboratory), hybridoma supernatants that produce a monoclonal antibody
against JCPyV VP1 or large T Antigen (TAg), respectively. Antibodies used for western blot analysis of
protein knockdown include: cRaf (CST), MEK1/2 (CST) and GAPDH (abcam). Antibodies and reagents
used for confocal immunofluorescence imaging include: cJun (CST), SMAD4 (CST), cMyc (CST) and DAPI
nuclear counterstain (Thermo Fisher Scientific). Secondary antibodies used for infectivity assays and
confocal immunofluorescence imaging include anti-mouse and anti-rabbit Alexa Fluor polyclonal 488
and 594 antibodies (Thermo Fisher Scientific). Antibodies and reagents used for ICW include: CellTag 700
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(Cell normalization stain) (LI-COR), pMEK (CST). Secondary LI-COR 800 anti-rabbit or anti-mouse
antibodies (LI-COR) were used for western blot and ICW protein detection analyses.
3.3.2. siRNA treatment

SVG-A cells were plated to 50% confluency in 12 well plates (Greiner Bio-One). Cells were
transfected with a scrambled (control), cRaf, MEK1, MEK2, or MEK1/2 siRNA using RNAiMax (Invitrogen)
per the manufacturer’s instructions. In brief, RNAiMax transfection reagent and siRNAs were prepared
in incomplete media (iMEM) (lacking FBS and antibiotics), combined, and incubated at RT for 5 min.
siRNA complexes were added to SVG-A cells and incubated at 37°C for 72 h. At 72 hpt cells were either
infected with JCPyV (MOI = 1 FFU/cell) at 37°C for 1 h or fixed with 4% PFA, washed with 1X PBS three
times and analyzed to confirm siRNA protein knockdown by western blot. Infected cells were fed with
cMEM and incubated at 37°C for 72 h. At 72 hpi, cells were fixed with 4% PFA, washed with 1X PBS three
times, and stained for VP1 by indirect immunofluorescence and quantitation of viral infection as
described.
3.3.3. Indirect immunofluorescence detection and quantitation of viral infection.

Following PFA fixation, SVG-A cells were permeabilized with 1X TBS- 1% Triton X-100 for 15 min
and were then incubated with 10% goat serum (Vector Labs) in 1X TBS-T at RT for 1 h while rocking. Cells
were stained with either PAB597 (VP1 Ab) (1:40) or PAB962 (1:3) (TAg Ab) in 1X TBS-T at 37°C for 1 h.
Cells were then washed with 1X TBS-T and incubated with an anti-mouse Alexa Fluor 488 antibody
(Thermo Fisher Scientific) at 37°C for 1 h and nuclei were counter stained with DAPI at RT for 5 min
(Thermo Fisher Scientific). Using a Nikon Eclipse Ti epifluorescence microscope (Micro Video
Instruments, Inc.), the number of VP1- or TAg-expressing cells per 10x visual field for 5 of visual fields
(per well) was quantitated. Percent infection was determined by dividing the number of infected cells
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per visual field by the total number of DAPI-positive nuclei per visual field as previously described [132].
As indicated, the average percent infection was normalized to the indicated control (100%).
3.3.4. ICW analysis of phosphorylation of host-cell proteins during JCPyV infection

SVG-A cells were plated to 70% confluency in 96 well plates. Cells were either mock-infected
(cMEM only) or infected with JCPyV (MOI = 1 FFU/cell) in cMEM at 37°C for 0, 5, 10, 30, or 60 min. At
indicated timepoints, cells were fixed in 4% PFA and washed in 1X PBS. Following PFA fixation, cells were
incubated with 1X TBS-1% Triton X-100 at RT for 15 min to permeabilize. Cells were then incubated with
TBS Odyssey Blocking Buffer (LI-COR) at RT for 1.5 h while rocking. Cells were stained with primary
antibody pMEK1/2 (1:500) in TBS Odyssey Blocking Buffer (LI-COR) at 4°C overnight while rocking. After
incubation with the primary antibody, cells were washed with 1X TBS-T and then incubated with the
rabbit LI-COR 800 secondary antibody (1:10,000) and CellTag 700 (1:500) at RT for 1 h while rocking.
Cells were then washed with 1X TBS-T three times and aspirated to remove all liquid prior to scanning.
Using a LI-COR Odyssey CLx, plates were scanned for 700 and 800 nm channel intensities. Plates were
read at a resolution of 42 m, at medium quality, and a 3.0 mm focus offset. After scanning, channels
were aligned using the Image Studio software (version 5.2) equipped with the In-cell Western module.
After scanning, the ICW analysis grid (Image Studio) was applied to the plate image to outline each well
and images were then processed using Image J (NIH) as previously described [134].
3.3.5. Global RT2 MAPK-ERK Profiler qPCR Array

SVG-A cells were mock infected or infected with JCPyV (MOI: 1 FFU/cell) and incubated at 37C
for 1 hr. Cells were fed with cMEM or DMEM and incubated at 37°C for 24 hr. At 24 hpi, RNA was
extracted from each sample with the SingleShot Cell Lysis kit (Bio-Rad) per manufacturer’s protocol.
Harvested RNA from each sample was converted to cDNA using iScript Reverse-Transcription Supermix
(Bio-Rad) with 1 g of RNA per reaction. cDNA prepared from mock-infected and JCPyV-infected
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samples was combined with the RT2 SYBR Green qPCR Master Mix (Qiagen), aliquoted into individual RT2
Profiler PCR Array plates (Qiagen), wells were capped and plates were centrifuged at 168 x g for 1 min.
PCR array plates were thermal cycled per the manufacturer’s instructions using a Bio-Rad CFX96 RealTime System, using Bio-Rad CFX Manager software 3.1. Calculation of the CT for genes for interest
(GOI) were determined using the average of three designated housekeeping genes (HKG) on each plate
(GOI CT – HKG CT). Calculation of CT for JCPyV infected samples was determined compared to mock
infected samples by (JCPyV GOI CT – Mock GOI CT) for relevant GOIs. The average fold change of GOI
transcript levels between mock infected and JCPyV infected cells was performed using 2 -CT of average
calculated GOI CT values. Average fold change of GOIs was determined by using samples from three
independent experiments.
3.3.6. Detection of transcription factors localization during ERK inhibition with confocal imaging

SVG-A cells were plated to 50% confluency in 14 mm glass bottom dishes (MatTek) in cMEM
containing 2% FBS (2% cMEM), and were incubated at 37°C overnight. Cells were then either treated
with 2% cMEM containing DMSO or U0126 (10 M) at 37°C for 48 h. At 48 h, both mock and infected
samples were fixed in 4% PFA and washed in 1X PBS three times. Following fixation, samples were
permeabilized with 1X TBS- 1% Triton X-100 at RT for 15 min and were then incubated with 10% goat
serum (Vector Labs) in 1X TBS-T at RT for 1 h while rocking. Cells were stained with antibodies for hostcell proteins cMyc (1:500) or SMAD4 (1:500) in 1X TBS-T at 37°C for 1 h. Cells were then washed with 1X
TBS-T and incubated with an anti-rabbit Alexa Fluor 488 antibody (Thermo Fisher Scientific) at 37°C for 1
h and nuclei were counter stained with DAPI.

Cells were visualized using a confocal microscope (Olympus Fluoview FV1000) using a 60X,
1.42NA oil immersion lens (Olympus). Images were acquired using the Olympus Fluoview application
suite. For each sample type, 30 cells were imaged per replicate across three independent experiments
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for a total of 90 cells per sample type. Images were analyzed for nuclear:cytoplasmic (N:C) ratios for
host-proteins of interest with ImageJ.
3.3.7. Detection of host and viral proteins during JCPyV infection with confocal imaging

SVG-A cells were plated to 50% confluency in 14 mm glass bottom dishes (MatTek) in cMEM
containing 2% FBS (2% cMEM), and were incubated at 37°C overnight. Cells were either mock infected
or infected with JCPyV (MOI= 2 FFU/cell) in 2% cMEM at 37°C for 1 h. Cells were then fed with 2% cMEM
and incubated at 37°C for 48 h. At the indicated timepoint, both mock and infected samples were fixed
in 4% PFA and washed in 1X PBS three times. Following fixation, samples were permeabilized with 1X
TBS- 1% Triton X-100 at RT for 15 min and were then incubated with 10% goat serum (Vector Labs) in 1X
TBS-T at RT for 1 h while rocking. Cells were stained with PAB962 (1:3) and antibodies for host-cell
proteins cJun (1:500), cMyc (1:500), or SMAD4 (1:500) in 1X TBS-T at 37°C for 1 h. Cells were then
washed with 1X TBS-T and incubated with an anti-rabbit Alexa Fluor 488 antibody (host-cell proteins)
(Thermo Fisher Scientific) and an anti-mouse Alexa Fluor 594 (TAg) (Thermo Fisher Scientific) at 37°C for
1 h and nuclei were counter stained with DAPI.

Cells were visualized using a confocal microscope (Olympus Fluoview FV1000) using a 60X,
1.42NA oil immersion lens (Olympus). Images were acquired using the Olympus Fluoview application
suite. For each sample type, 30 cells were imaged per replicate across three independent experiments
for a total of 90 cells per sample type. Images were analyzed for nuclear:cytoplasmic (N:C) ratios for
host-proteins of interest with ImageJ.
3.3.8. ImageJ quantitation of nuclear:cytoplasmic ratio of host proteins

Confocal images were processed for host-protein N:C ratios among mock and infected samples
in ImageJ as described [312]. In brief, maximum intensity projections of the DAPI (405), host-protein
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(488), and TAg (594) (if applicable) channels were generated and merged within a single sample. The
background was subtracted from each image using the rolling ball radius method. The DAPI (405)
nuclear stain was used to generate a nuclear mask of cells within the image excluding cells on the
periphery. The DAPI image threshold was adjusted, converted to a binary image, and analyzed to
generate nuclear regions of interest (ROIs). This nuclear mask was then applied to the host-protein (488)
channel, and the nuclear ROIs were measured, generating the mean nuclear intensity value of the hostprotein of interest. The nuclear mask was then dilated, new regions of interest were generated, and
were then applied to the host-protein channel to define the mean cytoplasmic intensity of the hostprotein of interest. The N:C ratios were then calculated as described [312]. Boxplots were generated
using MatLab.
3.3.9. Statistical analyses

Student’s t-test was used to compare means from at least triplicate samples in Microsoft Excel
to determine statistical significance. P-values < 0.05 were considered statistically significant. Each
experiment was performed in triplicate containing a minimum of triplicate samples. MatLab statistical
software was used to generate notched boxplots.
3.4. Results
3.4.1. Knockdown of Raf prevents JCPyV infection.
Prior studies have identified that JCPyV activates the MAPK-ERK cascade, specifically ERK, during
infection [46,132,313]. However, the mechanism by which ERK becomes activated during JCPyV
infection is currently unknown. During canonical host-cell MAPK-ERK signaling, the kinase Raf, directly
upstream of both ERK and MEK, serves as the initial kinase of the MAPK-ERK signaling cascade. Activated
by Ras-GTP activity, Raf facilitates the propagation of mitogenic signals to MEK and downstream to ERK.
As activation of the MAPK-ERK pathway proceeds in a linear fashion, if levels of phosphorylated ERK
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increase upon JCPyV challenge, it suggests that JCPyV must utilize the kinases upstream of this potent
signaling molecule to induce ERK activation, including Raf and MEK. Previous findings have
demonstrated that Bay43-9006, a chemical inhibitor of Raf signaling, prevents JCPyV infection in SVG-A
cells, suggesting Raf plays an important role in promoting JCPyV infection [134]. However, Bay-43-9006
has been shown to also inhibit receptor tyrosine kinase activity (RTK), which is also required for JCPyV
infection [46]. Due to potential effects of Bay43-9006 inhibition on proteins other than Raf, siRNA
knockdown of host-cell Raf proteins was employed as a more specific targeting mechanism for
investigating the role of Raf during JCPyV infection [134].
To confirm the necessity of Raf for successful JCPyV infection, SVG-A cells were transfected with
either a control or Raf siRNA, then infected with JCPyV, and infectivity was then scored by indirect
immunofluorescence and quantitation of nuclear VP1 expression. Raf siRNA-treated cells demonstrated
an ~80% reduction in infectivity in comparison to the control siRNA-treated cells suggesting that Raf is
necessary for promoting successful viral infection (Figure 3.1).
3.4.2. Knockdown of MEK prevents JCPyV infection.
The ERK1/2 proteins have been previously shown to play an essential role in facilitating viral
infection [46,132]. Raf protein knockdown through siRNA treatment reduced JCPyV infectivity (Figure
3.1), suggesting that the MAPK-ERK pathway is activated through Raf during JCPyV infection. Raf and
ERK are linked by the mitogen-activated protein kinase kinase (MEK), that directly phosphorylates ERK
[71,72]. MEK isoforms 1 and 2 are dual-specificity kinases, activating threonine and tyrosine residues on
both ERK1 and ERK2. Interestingly, ERK1/2 are currently the only know substrates of MEK [71],
highlighting its crucial role in both activating ERK and facilitating overall MAPK-ERK signaling. Recent
works have investigated the impacts of the MEK chemical inhibitors PD98059 and U0126 on JCPyV
infection and found that upon inhibition of MEK, viral infectivity was significantly reduced, suggesting a
pivotal role of MEK1/2 induction of ERK1/2 activity in facilitating viral infection [64,132]. To define the
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role of MEK1/2 in JCPyV infection, SVG-A cells were transfected with siRNAs specific for either MEK1,
MEK2, MEK1/2, or a control. Cells were subsequently infected with JCPyV, and infectivity was scored
based on the presence of nuclear VP1 expression. At 72 hpi, cells treated with MEK siRNAs
demonstrated decreased infectivity, ranging from 65-85% reduction in comparison to control siRNAtreated cells suggesting that both MEK1 and 2 are necessary for viral infection (Figure 3.2).

A

B

Figure 3.1. Knockdown of Raf inhibits JCPyV infection.
SVG-A cells were transfected with either a scrambled siRNA control or a Raf siRNA and incubated at 37C for 72 h.
At 72 hpt, siRNA-transfected cells were either (A) infected with JCPyV (MOI: 1 FFU/cell) at 37C for 1 h and then
fed with cMEM and incubated for 72 h or (B) harvested for western blot analysis of protein knockdown using Raf
and GAPDH antibodies. Infected cells were fixed and stained to analyze nuclear JCPyV VP1 expression. Data are
representative of the percentage of JCPyV VP1+ cells per visual field normalized to the siRNA control cells (100%).
Data are representative of three independent experiments. Error bars represent the standard deviation. Student’s
t-test was used to determine statistical significance. *P < 0.05.
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Figure 3.2. Knockdown of MEK1/2 inhibits JCPyV infection.
SVG-A cells were transfected with either a scrambled siRNA control, MEK1, MEK2, or MEK1/2 siRNA and incubated
at 37C for 72 h. At 72 hpt, siRNA-transfected cells were either (A) infected with JCPyV (MOI: 1 FFU/cell) at 37C
for 1 h and then fed with cMEM for 72 h or (B) harvested for western blot analysis of protein knockdown using
MEK1/2 and GAPDH antibodies. Infected cells were fixed and stained to analyze nuclear JCPyV VP1 expression.
Data are representative of the percentage of JCPyV VP1+ cells per visual field normalized to the siRNA control cells
(100%). Data are representative of three independent experiments. Error bars represent the standard deviation.
Student’s t-test was used to determine statistical significance. *P < 0.05.

3.4.3. JCPyV induces MEK activation upon infection.
Previous research has shown that JCPyV upregulates phosphorylation of ERK1/2 at early timepoints during viral infection, occurring at 15 min post-infection [46,132]. Activation of ERK1/2 is
facilitated directly through dual-phosphorylation by MEK during canonical signaling of the MAPK-ERK
cascade [71,72]. ERK1/2 proteins are currently the only identified substrates of the dual-specificity
kinase MEK, illuminating the highly-regulated nature of MEK activity and overall regulation of the MAPKERK pathway. As ERK is a critical regulator of JCPyV infection, the kinase responsible for its activation,
MEK, may also play an essential role in promoting JCPyV infection [132] (Figure 3.2). To determine if
JCPyV infection upregulates MEK1/2 activity following viral challenge, SVG-A cells were either mock
infected (lacking virus) or infected with JCPyV, fixed, and subsequently analyzed using an In-cell western
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(ICW) assay to quantitate levels of phosphorylated MEK1/2 (pMEK) during the early stages of infection
[134].
At timepoints as early as 5 mins post infection, pMEK levels were significantly higher in JCPyVinfected samples in comparison to mock-infected wells through 10 mins post infection, and
phosphorylation levels declined over the course of 1 h (Figure 3.3). These findings demonstrate that
JCPyV infection induces MEK1/2 activity prior to timepoints congruent with ERK activation during JCPyV
challenge [46,132], suggesting that JCPyV infection increases levels of phosphorylated MEK, leading to
increased activation of ERK. These data demonstrate that JCPyV infection utilizes multiple proteins
within the MAPK-ERK pathway to promote eventual ERK phosphorylation and overall infectivity.

Figure 3.3. Quantitation of MEK phosphorylation during JCPyV infection.
SVG-A cells were mock infected (cMEM only) or infected with JCPyV (MOI: 1 FFU/cell). Cells were then fixed at the
indicated timepoint and stained with antibodies targeting pMEK1/2 and Cell Tag (control) for ICW analysis using a
LICOR imaging system. The percentage of pMEK was quantitated by ICW signal intensity values per the calculation
[(pMEK/Cell Tag) *100] as determined through ImageJ analysis. Data are representative of three independent
experiments. Error bars represent the standard deviation. Student’s t-test was used to determine the statistical
significance. *P < 0.05.
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3.4.4. Gene expression of multiple MAPK-ERK-associated proteins and transcription factors are
upregulated during JCPyV infection.
Inhibition of essential MAPK-ERK proteins Raf, MEK, and ERK reduces JCPyV infection (Figures
3.1 and 3.2) [132], indicating that JCPyV relies on the MAPK-ERK pathway to promote infection of host
cells. However, the impact of this pathway on the numerous potential downstream targets in the MAPKERK pathway is uncharacterized. Like most cellular signaling mechanisms, the MAPK-ERK cascade is an
exceedingly complex network of proteins that interacts with a multitude of different substrates, engages
in cross-talk with other pathways, and ignites feedback loops that regulate further signaling propagation
[71,72]. Ultimately, these downstream effects can impact mitogenic induction of cellular processes like
growth and proliferation [71,72], which would be beneficial to a virus that is utilizing host-cell machinery
in order to facilitate genome replication. In the context of JCPyV infection, ERK has been identified as a
key regulator of JCPyV viral gene transcription [132], leading us to hypothesize that JCPyV-induced ERK
activation drives the activation of host-cell transcription factors. Several transcription factors have been
identified as being associated with canonical MAPK-ERK pathway including: Elk-1, SMADs, cJun, cMyc,
cFos, etc. [314]. Due to the potential MAPK-ERK-regulation of transcription factors and viral reliance on
host-cell transcription factors to drive transcription of viral genes, a global qPCR MAPK array was
employed to investigate whether gene expression of MAPK-specific transcription factors were
influenced during JCPyV challenge (Table 3.1).
SVG-A cells were infected with JCPyV or mock infected, RNA was harvested at 24 hpi, and cDNA
was generated and analyzed for the relative gene expression of MAPK-ERK-associated proteins and
transcription factors at 24 hpi. Interestingly, several transcription factors were upregulated in
comparison to mock-infected samples at 24 hpi including cMyc and SMAD4 (Table 3.1). The positive
upregulation of these transcription factors during infection suggests that JCPyV utilizes these MAPK-ERKassociated transcription factors to facilitate critical steps in the viral infectious process such as gene
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transcription. Both MEK and ERK were upregulated following JCPyV challenge as well as other MAPKassociated transcription factors (Table 3.1). Interestingly, other groups have identified some of these
specific transcription factors, including NFAT4 and p53, as necessary factors for facilitating JCPyV
infection [67,315], and thus these serve as internal experimental controls. Together, these data
suggestively link the utilization of these proteins during infection to viral activation of the MAPK-ERK
cascade.

Gene of Interest

Relative Fold Change (+)

CDKN1C

10.45

cMyc

6.46

ERK1

5.99

MAPK13

8.35

MEF2C

7.34

MEK2

5.62

NFAT4

13.28

p53

7.28

Raf

5.28

Rb1

6.75

SMAD4

4.58

Table 3.1. Global MAPK-ERK PCR Array genes of interest in JCPyV-infected cells.
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3.4.5. MAPK-ERK signaling regulates cMyc and SMAD4 cellular localization patterns.
JCPyV infection induces ERK phosphorylation early on in the infectious process [46,132,304],
however JCPyV requires this kinase activity to facilitate later steps in the viral lifecycle such as viral gene
transcription [132]. Further, the global MAPK-ERK PCR array revealed changes in gene expression of
several MAPK-associated transcription factors and associated proteins upon JCPyV challenge (Table 3.1).
Interestingly, regulation of ERK is heavily dependent on its spatial localization within the cell [72,314]. As
this spatial regulation of ERK occurs during prototypical MAPK signaling [306], JCPyV infection may
influence the localization of activated ERK to specific cellular compartments, including the nucleus, to
regulate necessary host-cell transcription factors to promote infection. Transcription factor targets of
activated ERK include cMyc and SMAD4, proteins that become activated upon mitogenic stimulation
[72], and intriguingly are also required for successful JCPyV infection [64,136]. Furthermore, as
expression of cMyc and SMAD4 is upregulated upon JCPyV infection (Table 3.1), MAPK-ERK activation
induced by JCPyV may facilitate TF accumulation in the infected host-cell nucleus.
To determine if ERK signaling directly influences transcription factor localization in glial cells,
SVG-A cells were treated with either DMSO or U0126 for 48 h and were subsequently assessed for cMyc
and SMAD4 protein localization. Using confocal imaging, U0126-treated cells were assessed for nuclear
versus cytoplasmic localization patterns for either cMyc or SMAD4 in comparison to DMSO-treated cells
at 48 hours post treatment (Figure 3.4). Through ImageJ analysis [312], nuclear and cytoplasmic regions
of interest (ROIs) were established to quantitate the signal intensity of the host protein of interest
between DMSO and U0126 treated cells in both the nucleus and cytoplasm of the single cell [312].
Through the generation of nuclear:cytoplasmic (N:C) ratios, potential shifts in localization patterning of
these transcription factors of interest during ERK inhibition was quantified. In comparison to DMSO
treated cells, SVG-A cells treated with the MEK inhibitor U0126 demonstrated decreased N:C ratios for
both cMyc (Figure 3.4A) and SMAD4 (Figure 3.4B). These findings demonstrate that ERK activity may
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promote the accumulation of both cMyc and SMAD4 into the host-cell nucleus during canonical MAPK
signaling. This link between the nuclear localization of both cMyc and SMAD4 and MAPK-ERK activity
suggests that JCPyV infection may specifically upregulate this robust signaling pathway in order to
promote viral gene transcription.

A

B

Figure 3.4. Transcription factor localization patterns during ERK inhibition.
SVG-A cells were treated with either U0126 (10 M) or DMSO (vehicle control) containing cMEM and incubated at
37C for 48 h, then fixed and processed for confocal imaging. Boxplots of (A) cMyc and (B) SMAD4 N:C ratios
quantified from confocal images of 30 individual cells. Whiskers represent values 1.5 times the distance between
the first and third quartiles (inter-quartile range). Boxplot notches denote the 95% confidence interval around the
median. Data are representative of N:C ratios from three independent experiments.

3.4.6. JCPyV induces altered nuclear protein intensity of MAPK-ERK-associated transcription factors.
The chemical inhibition of ERK activity results in decreased nuclear localization of key MAPKERK-associated transcription factors that play essential roles in promoting host-cell response to
mitogenic signals (Figure 3.4). However, little is currently understood regarding the translocation of
these transcription factors in response to JCPyV challenge. As JCPyV infection requires MAPK-ERK
signaling for viral gene transcription, the activation of this pathway during viral challenge may
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specifically facilitate the nuclear accumulation of transcription factors that have been previously shown
to be critical for viral infection [64,136].
To investigate the temporal localization of MAPK-regulated transcription factors in response to
JCPyV infection, SVG-A cells were infected with JCPyV or mock infected, then fixed and stained for both
the viral early gene product TAg and a host-cell transcription factor target of MAPK-ERK: cMyc, SMAD4,
or cJun. Infected cells expressing TAg were assessed for nuclear versus cytoplasmic localization for the
transcription factors of interest in comparison to their mock-infected cell counterparts at 48 hpi (Figure
3.5). Using ImageJ analysis to characterize both nuclear and cytoplasmic ROIs, the localization patterns
of key transcription factors was characterized in JCPyV infected cells. In comparison to mock-infected
cells, SVG-A cells challenged with JCPyV demonstrated increased N:C ratios for both cMyc and SMAD4 in
TAg-expressing cells. These findings suggest that JCPyV infection promotes an increase in the nuclear
localization of both cMyc and SMAD4 transcription factors during the infectious process. Conversely, the
relative N:C ratio of cJun localization in JCPyV-infected cells decreased in comparison to mock-infected
cells indicating that JCPyV does not require the cJun transcription factor activity at 48 hpi. These findings
corroborate established work that reports low expression levels of cJun in JCPyV-infected cells between
24-72 hpi [309]. Together these findings demonstrate that JCPyV infection alters the normal expression
levels and localization patterns of MAPK-ERK-associated transcription factors including cMyc and
SMAD4, potentially highlighting a resultant mechanism of JCPyV-induced MAPK-ERK activation for viral
transcription.
3.5. Discussion

Previous studies have identified the critical role of ERK, a key member of the MAPK pathway, in
promoting JCPyV infection [132]. However, the function of the MAPK signaling cascade and the pathway
responsible for ERK activation, had yet to be elucidated. The findings presented herein have identified
that the additional core kinases that comprise the MAPK-ERK pathway, Raf and MEK, each play
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necessary roles in promoting JCPyV infection. The initial kinase of this cascade, Raf, was shown to be
necessary for infection (Figure 3.1), suggesting that JCPyV may indeed induce the prototypical MAPK
signaling cascade in order to activate ERK. The necessity of the downstream kinase MEK was also
characterized through the siRNA knockdown of MEK in SVG-A cells. Upon protein knockdown of MEK,
the percentage of infected cells was significantly diminished, suggesting that MEK also plays a vital role
in successful JCPyV infection (Figure 3.2).
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Figure 3.5. MAPK-regulated transcription factor localization during JCPyV infection.
SVG-A cells were infected with JCPyV (MOI: 1 FFU/cell) and incubated in cMEM at 37°C for 48 h, then fixed and
processed for confocal imaging. (A/C/E) Representative confocal images demonstrating cMyc, SMAD4, and cJun
(green) cellular localization patterns during mock or JCPyV infection, as measured by TAg expression (red). Cell
nuclei stained with DAPI (blue). Scale bars = 10 m. (B/D/F) Boxplots of cMyc, SMAD4, or cJun N:C ratios quantified
from confocal images of 30 individual cells. Whiskers represent values 1.5 times the distance between the first and
third quartiles (inter-quartile range). Boxplot notches denote the 95% confidence interval around the median. Data
are representative of N:C ratios from three independent experiments.

86

To determine if JCPyV infection initiates the activation of MEK to facilitate infection,
phosphorylation levels of MEK1/2 were assessed post-viral challenge utilizing the ICW technique, which
demonstrated that JCPyV stimulates MEK1/2 activation at 5-10 mins post-challenge (Figure 3.3). While
the activation of MEK during JCPyV infection occurs between 5 and 10 minutes post-infection, this
activation is prior to the increase in ERK phosphorylation previously identified [132]. The earlier
activation of the upstream kinase MEK, suggests that ERK activation upon JCPyV infection requires the
initiation of canonical MAPK-ERK phosphorylation events, including the activation of MEK. Together,
these findings demonstrate the JCPyV utilizes multiple facets of the MAPK-ERK pathway to promote
productive infection in glial cells.

Signal transduction through the MAPK-ERK cascade ultimately stimulates a cellular response
through the activation of multiple effector proteins including transcription factors [71,72,306].
Furthermore, JCPyV requires MAPK-ERK signaling to promote infection, particularly in order to promote
viral gene transcription [132]. Data presented herein suggest that JCPyV may require the activation of
the MAPK-ERK cascade to target downstream proteins of this pathway to facilitate these cellular
transcriptional processes. Using a global MAPK qPCR array, multiple genes associated with the MAPKERK pathway were identified to be upregulated during JCPyV infection (Table 3.1). Multiple reports have
previously identified multiple host-cell transcription factors usurped by JCPyV during infection including:
cMyc, AP-1 (cJun and cFos), NFAT4, SMAD4, YB-1, NF-1, and others [64,67,68,136,309-311].
Interestingly, many of these transcription factors are downstream effectors of the MAPK-ERK signaling
cascade. The increased cMyc, SMAD4, and NFAT4 gene expression levels upon JCPyV infection identified
using the MAPK global PCR array suggest that MAPK-ERK activation may facilitate the upregulation of
these transcription factors during JCPyV infection.
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As the spatiotemporal regulation of canonical MAPK signaling plays a critical role in targeting
specific downstream proteins like transcription factors, the localization patterns of the identified
transcription factors were measured during viral infection. Under normal cellular conditions, both cMyc
and SMAD4 can localize to cytoplasmic and nucleoplasmic regions within the cell, while cJun is highly
retained in the nucleoplasm [316,317]. However, JCPyV infection has been previously shown to induce
alterations to transcription factor localization patterning in the case of SMAD4 [64]. Ravichandran et al.
have shown that upon treatment with transforming growth factor- 1 (TGF-1), the kinase MEK is
activated, and the SMAD2/4 complex translocates from the cytoplasm into the nucleus, thereby
enhancing JCPyV replication [64]. To confirm the link between JCPyV activation of the MAPK-ERK
pathway and the translocation of transcription factors into the nucleus, transcription factor localization
patterns during ERK inhibition was analyzed by confocal microscopy. Indeed, the nuclear accumulation
of both cMyc and SMAD4 was dampened upon treatment with U0126, suggesting that MAPK-ERK
signaling facilitates cMyc and SMAD4 nuclear localization (Figure 3.4).

As cMyc and SMAD4 nuclear accumulation relies on proper ERK signaling, the direct stimulation of
this pathway during viral challenge may further highlight the role of the MAPK-ERK signaling cascade in
JCPyV genome transcription. To characterize the link between JCPyV activation of ERK and the
requirement of proper MAPK-ERK signaling for transcription factor nuclear localization, the localization
of these MAPK-ERK-associated transcription factors was assessed during JCPyV infection using confocal
microscopy. The nuclear to cytoplasmic ratios for both cMyc and SMAD4 at 48 hpi indicate that these
transcription factors localize in the nucleus over the cytoplasm of infected cells (Figure 3.5). These data
suggest that not only are these transcription factors necessary for viral infection, but that the increase in
nuclear localization patterning may in part be due to JCPyV-induction of the MAPK-ERK signaling
cascade, in line with the previously published work [64]. Together, these findings suggest that the
MAPK-ERK pathway on the whole, plays a critical role in facilitating viral infection and that viral
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induction of this pathway may be required for the localization of MAPK-ERK-associated transcription
factors into the host-cell nucleus for viral gene transcription.

In addition, another transcription factor found to be upregulated upon JCPyV infection, was the
myocyte enhancer factor 2C (MEF2C), a protein yet to be associated with JCPyV infection. MEF2C is
ubiquitously expressed in the CNS, where it plays a critical role in neuronal development through
synaptic formation [318]. Interestingly, this enhancer was found to be critical for Epstein-Barr virus
(EBV) induction of cMyc, a protein necessary for EBV transformation of B cells [252]. EBV, a similar DNA
virus to that of JCPyV, also utilizes the MAPK-ERK pathway in order to facilitate viral infection [234,235].
Future studies will explore the role of MEF2C in JCPyV infection and investigate whether MEF2C
regulates cMyc expression during infection.
The MAPK-ERK pathway plays critical roles in promoting important cellular processes such as
growth, differentiation, proliferation, and pro-survival signaling. These requisite cellular activities are
also targeted by most human DNA viruses during the infectious process, as manipulating these
mechanisms is key to promoting successful viral infection of the host. With a small genome size, JCPyV
only encodes for six protein-coding genes, necessitating that each of these eventual viral proteins act in
multiple capacities to promote infection. Capitalizing on endogenous host-cell mechanisms that are
responsible for multiple cellular fates is one way that viruses can effectively function with such a limited
genetic toolkit. Indeed, many human DNA viruses utilize MAPK-ERK signaling, often to facilitate viral
replication, dysregulate the cell-cycle, alter host immune responses or even promote cell survival [313].
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CHAPTER 4
HIGH-THROUGHPUT CHARACTERIZATION OF VIRAL AND CELLULAR PROTEIN EXPRESSION PATTERNS
DURING JC POLYOMAVIRUS INFECTION
This chapter represents a modified form of the published work from: DuShane JK, Wilczek MP, Crocker
MA and Maginnis MS (2019) High-Throughput Characterization of Viral and Cellular Protein Expression
Patterns During JC Polyomavirus Infection. Front. Microbiol. 10:783. Reproduction of the published work
for thesis is permitted by the publisher Frontiers.

4.1. Chapter Summary
JC polyomavirus is a ubiquitous human pathogen and the causative agent of a fatal demyelinating
disease in severely immunocompromised individuals. Due to the lack of successful pharmacological
interventions, the study of JCPyV infection strategies in a rapid and highly-sensitive manner is critical for
the characterization of potential antiviral therapeutics. Conventional methodologies for studying viral
infectivity often utilize the detection of viral proteins through immunofluorescence microscopy-based
techniques. While these methodologies are well established in the field, they require significant time
investments and lack a high-throughput modality. Scanning imager-based detection methods like the Incell Western (ICW), have been previously utilized to overcome these challenges incurred by traditional
microscopy-based infectivity assays. This automated technique provides not only rapid detection of viral
infection status, but can also be optimized to detect changes in host-cell protein expression during
JCPyV challenge. Compared to traditional manual determinations of infectivity through microscopybased techniques, the ICW provides an expeditious and robust determination of JCPyV infection. The
optimization of the ICW for the detection of viral and cellular proteins during JCPyV infection provides
significant time and cost savings by diminishing sample preparation time and increasing resource
utilization. While the ICW cannot provide single-cell analysis information and is limited in the detection
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of quantitation of low-expressing proteins, this assay provides a high-throughput system to study JCPyV,
previously unavailable to the field. Thus, the high-throughput nature and dynamic experimental range of
the ICW can be applied to the study of JCPyV infection.
4.2. Introduction
While significant advances have been made in the characterization of JCPyV replication strategies,
JCPyV research productivity has been hindered by the lack of a productive animal model and limited
cellular tropism [23,319]. Currently, the study of JCPyV relies heavily on manual microscopic analysis of
cell-culture based assays to characterize infectivity [10]. The most widely used assay to measure JCPyV
infectivity is the fluorescent focus unit (FFU) assay, which requires viral protein-specific antibodies to
label infected cells for detection via epifluorescence microscopy [320,321]. While the FFU assay is a
reliable and well-characterized virological method, it presents several challenges: it can introduce
observer bias, often relies on partial sample analysis to generate representative data, and requires a
significant time investment that reduces research productivity and limits the feasibility of large-scale
screens. To address these issues, other technologies, like the pseudovirus system, have been generated
to enable high-throughput data collection of JCPyV infectivity [322,323]. However, this system relies on
virus-like particles that lack infectious DNA, and thus can only provide insights into the early steps in the
viral lifecycle. In contrast, the In-cell Western assay (ICW), has been shown to effectively quantitate
viral infection using infectious viruses like influenza, herpes simplex virus, reovirus, and rotaviruses by
employing a high-throughput laser-based scanning technology [324-326]. The ICW employs a similar
method to that of indirect immunofluorescence staining, yet utilizes a secondary near infrared (NIR)conjugated antibody labeling system. Data regarding viral infection can then be obtained with this
automated infrared imaging system, eliminating observational biases and greatly reducing the time
needed to reliably quantitate infectivity data.
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The goal of this study was to adapt the ICW assay as a reliable method to enable high-throughput
study of JCPyV infection to enhance the rate of discovery and improve the feasibility of large-scale
screens. To this end, the ICW has been shown to accurately characterize JCPyV infectivity at variable
levels of infection, including viral inhibition through chemical and siRNA treatments, and for the
quantification of host-cell protein expression during viral challenge. These findings demonstrate that the
ICW assay provides an effective measure of viral infection and can be utilized as a platform for highthroughput screening of JCPyV infectivity (Figure 4.1).
4.3.

Materials and Methods

4.3.1. Cell types and viruses

Human fetal glial SVG-A cells were cultured in Minimum Essential Medium (Corning)
supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals), 1% penicillin/streptomycin (P/S)
(Mediatech, Inc.) and 0.2% Plasmocin prophylactic (Invivogen) (cMEM). Cells were maintained in a
humidified incubator at 37°C with 5% CO2. SVG-A cells [267] were generously provided by the Atwood
laboratory (Brown University) and have been authenticated by ATCC through STR profiling. Viral
infections were performed with a purified JCPyV strain Mad-1/SVE as previously described [48], or
SV40 strain 777. Virus strains were generously provided by the Atwood laboratory.
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Figure 4.1. Graphical representation of ICW technique.
The plate-based ICW assay provides quantitative measure of immunofluorescence in a high-throughput modality.
Artistic credit: Michael Wilczek.

4.3.2. Cell stains and antibodies

Commercially available ab34756 (Abcam) and a monoclonal antibody derived from a hybridoma
supernatant (PAB597) (generously provided by the Atwood laboratory) [35] were used to probe for the
JCPyV major capsid protein VP1 to quantitate JCPyV infection. PAB597 cross-reacts with the SV40 VP1
protein [35] and was also used to score SV40 infectivity. Antibodies for ERK1/2 (ERK) (CST #4695),
phosphorylated ERK1/2 (pERK) (CST #9101), or GAPDH (Abcam, ab8245) were used for ICW or western
blot protein quantifications. For the ICW, LI-COR 800 anti-mouse or anti-rabbit secondary antibodies (LICOR) were used. For FFU, Alexa Fluor 488 (Thermo Fisher Scientific) anti-mouse or anti-rabbit secondary
antibodies were used. CellTag 700 (LI-COR) was used as a cell count normalization stain for ICW assays
as indicated. DAPI nuclear counterstain (Thermo Fisher Scientific) was used as a cell count normalization
stain for FFU assays.
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4.3.3. Chemical treatments and siRNAs

Chemical inhibitors of MEK, U0126 and PD98059 (Cell Signaling Technology), were used at
concentrations of 10 M and 50 M, respectively. Bay43-9006 (Cayman Chemical), a chemical inhibitor
of Raf, was used at 15 M. Retro2 (Sigma Aldrich), a retrograde trafficking inhibitor, was used at a
concentration of 100 M [270]. All chemical inhibitors were reconstituted in DMSO (Cell Signaling
Technology), which served as a volume-specific vehicle control. EGFR and ERK1/2 siRNAs (Cell Signaling
Technology) were transfected into SVG-A cells with RNAiMax (Thermo Fisher) at 10 pmol per well per
manufacturer’s instructions. Successful transfections of the siRNAs were confirmed using BLOCK-iT Red
(Thermo Fisher) [132].

4.3.4. JCPyV and SV40 infectivity at varying MOIs

SVG-A cells were infected with JCPyV and SV40 at MOIs indicated per figure legend in cMEM at
37°C for 1 h. Cells were then fed with cMEM, and plates were incubated at 37°C for 72 h. At 72 hpi, cells
were washed with 1X PBS, fixed in 4% PFA at RT for 10 min, and washed three times in 1X PBS prior to
staining for either ICW or FFU.

4.3.5. Chemical inhibition of JCPyV infectivity

SVG-A cells were plated to ~70% confluency in 96 well plates. Cells were pre-treated with cMEM
containing DMSO, U0126, PD98059, Bay43-9006, or Retro2 at 37°C for 1 h. Following pre-treatment,
cells were infected with JCPyV (MOI = 0.5 FFU/cell) at 37°C for 1 h. Media containing the indicated
treatment was then added back to appropriate wells at 37°C for 72 h with the exception of Bay43-9006treated wells. Bay43-9006-treated wells were incubated for at 37°C for 2 h following infection,
aspirated, washed with 1X PBS, and cMEM was added back for the duration of the experiment. At 72 hpi
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cells were fixed in 4% PFA, washed with 1X PBS three times and FFU and ICW plates were stained as
described.

4.3.6. siRNA inhibition of JCPyV infectivity

Prior to siRNA transfection, SVG-A cells were plated to ~50% confluency in 12 well plates
(Greiner Bio-One). Cells were then transfected with an EGFR or ERK1/2 siRNA with RNAiMax. The
RNAiMax transfection reagent and siRNAs were diluted in incomplete MEM (lacking FBS and antibiotics),
combined, and incubated at RT for 5 min. siRNA complexes were added to SVG-A cells and incubated at
37°C for 72 h. At 72 hpt cells were infected with JCPyV (MOI = 0.5 FFU/cell) at 37°C for 1 h. Cells were
then fed with cMEM and incubated at 37°C for 72 h. At 72 hpi, cells were fixed with 4% PFA, washed
with 1X PBS three times, and stained for VP1 for FFU and ICW assays as described.

4.3.7. Fluorescent focus unit assay staining and quantitation of viral infection
Following fixation, cells were permeabilized with 1X TBS-1% Triton X-100 at RT for 15 min and
were then incubated with TBS Odyssey Blocking Buffer (LI-COR) at RT for 1.5 h. Cells were stained with
the primary antibodies PAB597 (JCPyV or SV40 VP1, 1:40) or ab34756 (JCPyV VP1, 1:1000) in TBS
Odyssey Blocking Buffer (LI-COR) at 4°C overnight while rocking. After primary incubation, cells were
washed with 1X PBS and incubated with either an anti-mouse or anti-rabbit Alexa Fluor polyclonal 488
antibody (Thermo Fisher Scientific) at RT for 1 h while rocking and nuclei were counter stained with DAPI
(Thermo Fisher Scientific). Using a Nikon Eclipse Ti epifluorescence microscope (Micro Video
Instruments, Inc.), the number of infected cells per 10x visual field was quantitated. Percent infection
was determined by dividing the number of infected cells/field by the total number of DAPI-positive
nuclei/field as previously described [132], reported as percent infection. As indicated, the average
percent infection was normalized to the highest MOI, vehicle control DMSO, or siRNA controls (set at
100%).
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4.3.8. ICW verification of host-cell protein knockdown
To confirm ERK1/2 host-cell protein knockdown by ICW, SVG-A cells transfected with EGFR and
ERK1/2 siRNAs (as described) were fixed at 72 hpt with 4% PFA. Cells were washed with 1X PBS three
times and stained for total ERK and CellTag for ICW analysis with the LI-COR Odyssey CLx.
4.3.9. In-cell western assay staining and protein quantification

Following fixation, cells were incubated with 1X TBS-1% Triton X-100 to permeabilize for 15 min.
Cells were then incubated with TBS Odyssey Blocking Buffer (LI-COR) at RT for 1.5 h while rocking. Cells
were stained with primary antibodies as indicated: PAb597 (1:40), ab34756 (1:1000), ERK1/2 (1:500), or
pERK1/2 (1:500) in TBS Odyssey Blocking Buffer (LI-COR) at 4°C overnight while rocking. After primary
incubation, cells were washed with 1X TBS-T and incubated with either an anti-mouse or anti-rabbit LICOR 800 secondary antibody (1:10,000) and CellTag 700 (1:500) at RT for 1 h while rocking. Secondaryalone wells were treated only with species-appropriate LI-COR 800 secondary antibody (1:10,000). Cells
were washed with 1X TBS-T three times and aspirated to remove all liquid prior to scanning. Using a LICOR Odyssey CLx Infrared Imaging system, plates were immediately scanned to detect 700 and 800 nm
channel intensities. Plates were read at a 42 m resolution, at medium quality, with a 3.0 mm focus
offset. After scanning, 700 and 800 nm channels were aligned using the Image Studio software (version
5.2) equipped with the In-cell Western module. After scanning, the ICW analysis grid (Image Studio) was
applied to the plate image to outline each well and images were then processed using Image J (NIH).

4.3.10. Western blot verification of host-cell protein knockdown
Western blot analysis of ERK1/2 protein expression was also used to confirm siRNA protein
knockdown. SVG-A cells were transfected with either EGFR or ERK1/2 siRNAs as described above. Cells
were then washed with 1X PBS and manually scraped from sample wells. Cells were pelleted by
centrifugation at 376 x g 4°C for 5 min. Pellets were resuspended in 50 μl of Tris-HCl lysis buffer
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containing protease and phosphatase inhibitors and incubated on ice for 15 min. Samples were
centrifuged at 18,600 x g at 4°C for 10 min. Samples were combined with Laemmli sample buffer (BioRad), boiled at 95C for 5 min, and proteins were then resolved by SDS-PAGE using a 4-15% gel (BioRad). Proteins were transferred onto a nitrocellulose membrane with a Transblot Turbo Transfer System
(Bio-Rad). Protein-containing membranes were then blocked with 5% non-fat dry milk/TBS-T (1X
TBS/0.1% Tween 20) overnight at 4°C while rocking. Membranes were washed with 1X TBS-T for 15 min,
three times. Membranes were then incubated with primary antibodies for total ERK (1:500) and GAPDH
(1:2000) in 5% BSA/TBS-T overnight at 4°C while rocking. After primary antibody incubation, membranes
were washed in TBS-T at RT for 15 min three times each and then incubated with the secondary antirabbit 680 antibody (1:10,000) (LI-COR) and anti-mouse 800 antibody (1:10,000) (LI-COR) at RT for 1 h in
5% milk/TBS-T. Membranes were washed in TBS and then imaged using a LI-COR Odyssey CLx.
4.3.11. JCPyV-induced activation of ERK

SVG-A cells were plated to ~70% confluency in 96 well plates. Cells were either mock-infected
(cMEM only) or infected with JCPyV (MOI = 0.5 FFU/cell) in cMEM at 37°C for 0, 15, 30, or 60 min. At the
indicated timepoints, cells were fixed in 4% PFA at RT for 10 min and washed three times in 1X PBS.
After fixation, both mock- and JCPyV-infected wells were probed for pERK and CellTag for ICW analysis
with the LI-COR Odyssey CLx.

4.3.12. Image J analysis of ICW-plate images
Each plate processed for ICW was scanned using the LI-COR Odyssey CLx imager, and a sizespecific plate template was added to the image containing both 700 and 800-channel intensities to
define well boundaries. Each image was subsequently loaded into ImageJ for analysis, adapted from
previous models [312,327]. In brief, RGB ICW image channels were split and a background subtraction
was applied to the 8-bit, red and green channels, in accordance to well size, using the rolling ball radius
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algorithm. To measure signal intensity within each well, a mask of each well was generated from the
aforementioned size-specific template as regions of interest (ROI). The ROIs generated from the
template image were then applied to both the 700 (red) and 800 (green) images, and the fluorescence
intensities from each well (as characterized per pixel) were generated. To account for background
fluorescence intensity from uninfected or untreated wells (mock), the mock sample (as experimentally
indicated) intensity values for both the 700 and 800 channels were subtracted from experimental wells
to account for non-specific fluorescence. Resultant values were plotted using the ggplot2 R package
(version 3.5.1) [328] and reported as percent response.
4.3.13. Statistical analyses

Student’s t-test was used to compare means from at least triplicate samples in Microsoft Excel to
determine statistical significance. P values <0.05 were considered statistically significant. Each
experiment was performed in triplicate containing a minimum of triplicate samples. Pearson correlation
coefficients, calculated using R, were used to correlate manual microscopy FFU (percent infection) data
with corresponding ICW (percent response) data as indicated.

4.4. Results
4.4.1. Characterization of JCPyV Infectivity by ICW
To determine whether the ICW can be used to accurately quantitate JCPyV infection, SVG-A cells
were infected with varying JCPyV MOIs and analyzed for infectivity using manual FFU quantitation
(percent infection) and ICW (percent response) analyses performed in parallel (Figure 4.2A and 4.2B).
The Cell Tag 700 (ICW) and DAPI stain (FFU) were used as total cell number normalization controls to
quantify the percentage of infected cells. Infectivity was characterized through measurement of newlysynthesized VP1 at 72 hpi, which represents a single replication cycle. Both the percent infection and
percent response data demonstrate an increase in VP1 expression with increasing MOIs. Interestingly,
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the percent infectivity and percent response data were positively correlative across the range of the
varying MOIs tested, as demonstrated by a Pearson correlation coefficient of 0.978 (Figure 4.2C). These
data indicate that the ICW is a robust and accurate assay for scoring JCPyV infectivity.

Figure 4.2. Quantitation of JCPyV infection by FFU and ICW.
SVG-A cells were infected with JCPyV at indicated MOIs (FFU/cell) at 37C for 1 h . At 1 hpi, cells were fed with
cMEM and incubated for 72 h. At 72 hpi, cells were fixed and stained for VP1 expression. JCPyV VP1 expression
was analyzed by ICW and FFU quantitation. (A) ICW plates were stained with CellTag 700 (red) and a LI-COR-800
secondary antibody to target VP1 (green). ICW infectivity (percent response) was quantified using a LI-COR
Odyssey CLx infrared imager equipped with Image Studio software and processed with ImageJ. FFU plates were
stained for VP1 and counterstained with DAPI as a cell count normalization control. (B) FFU quantification of VP1
(percent infection) was scored using a Nikon epifluorescence microscope and NIS Elements software. For each
experimental assay, a minimum of triplicate samples were analyzed and the percent infection or percent response
of a given MOI was normalized to the highest MOI, which was set to 100%. Error bars are representative of the
standard deviation from the mean. (C) ICW and FFU data were compared across identical conditions by linear
regression and an experimental correlation was determined using a Pearson correlation coefficient. The grey
shaded region represents the confidence interval (standard error of the linear regression). Data are representative
of three independent experiments.
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4.4.2. Quantification of JCPyV Infectivity by ICW Following Chemical Inhibition

A key protein necessary for productive JCPyV infection is the host-cell protein extracellular
signal-regulated kinase (ERK), a member of the mitogen-activated protein kinase (MAPK) cascade. It has
been previously shown that chemical inhibition of ERK significantly reduces JCPyV infection [132]. ERK
functions as the terminal kinase of the MAPK cascade and is directly phosphorylated by MEK, which is
activated by the kinase Raf [71]. It has been previously shown that inhibitors of MEK (U0126 and
PD98059) can be applied to cultured cells to inhibit the activation of the downstream target ERK
[329,330], thereby impacting JCPyV infection [64,132]. Moreover, as Raf is critical for the downstream
activation of ERK, chemical inhibition of Raf (Bay43-9006) was also investigated to determine if viral
infection was impacted.

To characterize viral infectivity in the presence of the aforementioned MAPK inhibitors, SVG-A
cells were pretreated with DMSO (vehicle control), Bay43-9006, PD98059, or U0126 and subsequently
infected with JCPyV (Figure 4.3). A cell viability assay (MTS) was used to confirm that chemical inhibitors
were not toxic (data not shown) and total cell numbers are accounted for through CellTag (ICW) and
DAPI staining (FFU). Cells were fixed and stained for VP1 using both FFU and ICW assays performed in
parallel. SVG-A cells treated with the inhibitor Bay43-9006 demonstrated an ~60% decrease in infection
in the case of both the FFU and ICW analyses, in comparison to controls (Figure 4.3A). The MEK inhibitor
PD98059 decreased JCPyV infectivity by ~80% as measured by FFU and ICW (Figure 4.3B). U0126
reduced JCPyV infectivity by ~60% in both the FFU analysis and the ICW quantitation of JCPyV VP1
expression (Figure 4.3C). In addition, the retrograde trafficking inhibitor Retro2, which has been
previously demonstrated to inhibit JCPyV infection [270], was tested as a JCPyV inhibitor via ICW.
Treatment of SVG-A cells with Retro2 significantly reduced JCPyV infection by ~90% as measured by FFU
and ~80% by ICW (Figure 4.3D), suggesting that an inhibitor of another component of the viral infectious
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cycle, viral trafficking, can be assessed by ICW. These data demonstrate the versatility of the ICW
analysis in the characterization of viral infection during chemical inhibition.

4.4.3.

Assessment of JCPyV Infectivity Following Protein Silencing

Treatment of SVG-A cells with an ERK1/2-specific siRNA has been previously shown to
significantly decrease JCPyV infection as measured by FFU quantitation [132]. To determine whether
siRNA-induced protein knockdown can be detected by the ICW, SVG-A cells were transfected with either
an irrelevant EGFR- or an ERK1/2-specific siRNA. In parallel, siRNA transfected SVG-A cells under the
same conditions were also processed by western blot to confirm that the ICW provides an accurate
measure of protein expression. ERK protein expression was reduced in samples transfected with the
ERK1/2 siRNA in comparison to the EGFR control for both the ICW and western blot assays (Figure 4.4A
and 4.4B), suggesting that the ICW is a viable method for protein expression analysis during siRNA
transfection.

To determine if the ICW can be used to quantitate JCPyV infection during siRNA conditions, SVGA cells were transfected with the aforementioned siRNAs and cells were subsequently infected with
JCPyV. Quantification of VP1 by FFU and ICW showed significant decreases of ~90% for both percent
infection and percent response (Figure 4.4C), suggesting that the ICW can be utilized to quantitate JCPyV
infection during siRNA transfection with the same degree of accuracy as traditional FFU assays.
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Figure 4.3. Chemical inhibition of host-cell protein activation inhibits JCPyV infection.
SVG-A cells were pre-treated with cMEM containing either DMSO (volume specific vehicle control), (A) Bay43-9006
(15µM), (B) PD98059 (50µM), (C) U0126 (10µM), or (D) Retro2 (100µM) at 37C for 1 h. Cells were then infected
with JCPyV (MOI = 0.5 FFU/cell) at 37C for 1 h. At 1 hpi, treated media was added back to the appropriate wells
for 72 h with the exception of wells with Bay43-9006-containing medium, which was removed at 2 hpi, and
replaced with cMEM for the duration (72 h). At 72 hpi, cells were fixed and stained for JCPyV VP1 expression for
ICW and FFU as previously described for each assay type. For each experimental assay, triplicate samples were
analyzed and the percent infection or percent response for each treatment was normalized to the DMSO control,
which was set to 100%. Error bars represent the standard deviation from the mean. *, P < 0.05. Data are
representative of three independent experiments.

4.4.4. JCPyV Infection Impacts on Host-cell Protein Expression
Previous research has demonstrated that early events during JCPyV infection induce alterations
to the MAPK pathway resulting in phosphorylation of ERK [46,132]. Within 15 minutes of viral challenge,
phosphorylated ERK (pERK) is highly upregulated in SVG-A cells [46,132]. Traditionally, quantitation of
protein phosphorylation has been measured through western blotting techniques, which can be
laborious and time consuming. However, the ICW has been implemented as an effective tool for the
102

quantitation of both protein expression and signal transduction [331-334], but has had limited use in
conjunction with the study of viral infectivity [334]. We employed the ICW technique to determine if
alterations to pERK levels during JCPyV infection could be quantified using the ICW methodology, SVG-A
cells were either mock-infected or infected with JCPyV, and levels of pERK were assessed by ICW over a
time course of infection. At 15 min post viral challenge, activation of ERK peaked, followed by a steady
decline through 1 hpi (Figure 4.5). These findings are in line with previously-published work
demonstrating that levels of pERK are highly upregulated in JCPyV-infected samples in comparison to
mock-infected SVG-A cells at early timepoints during infection [46,132]. These results demonstrate that
the ICW can not only assess viral infectivity, but can also quantify host-cell protein response to viral
infection.
4.4.5. ICW Analysis of Infectivity by Other Polyomaviruses

SV40 is the most phylogenetically related polyomavirus to JCPyV and has a very similar replication
cycle [335]. Thus, it was hypothesized that ICW can be utilized to quantify and characterize SV40
infectivity as well. To determine whether the ICW technique could be applied to SV40, SVG-A cells were
infected with varying MOIs of SV40. Cells were then incubated for 72 h and stained for SV40 VP1
expression and analyzed by FFU and ICW (Figure 4.6A and 4.6B). Resultant data from both FFU and ICW
demonstrated an increase in VP1 expression that correlated with increasing MOI (Figure 4.6C).
Moreover, infectivity quantified by FFU and ICW proved to be positively correlative as per a Pearson
correlation coefficient of 0.985, suggesting that the ICW is a viable and accurate measure of SV40
infectivity (Figure 4.6C).
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Figure 4.4. Quantitation of ERK siRNA inhibition of JCPyV infection by ICW.
SVG-A cells were transfected with either an irrelevant EGFR control or ERK1/2 siRNA and incubated at 37C for 72
h. (A) ICW analysis of the siRNA-transfected cells was used to confirm ERK1/2 knockdown using an antibody
targeting ERK1/2 (green) and CellTag (red) to normalize to the total number of cells present. (B) Western blot
analysis of cell lysates from siRNA-transfected cells were also analyzed to confirm ERK1/2 knockdown, using
antibodies specific for ERK1/2 (red) and GAPDH (green) (loading control). (C) At 72 hpt, siRNA-transfected cells
were infected with JCPyV (MOI = 0.5 FFU/cell) at 37C for 1 h and then fed with cMEM for 1 hpi. At 72 hpi, FFU and
ICW plates were fixed and stained as previously described for each assay type for JCPyV VP1 expression.
Distribution trends between triplicate samples are represented by violin plot for both ICW and FFU. *, P < 0.05.
Data are representative of three independent experiments.
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Figure 4.5. JCPyV-induced ERK activation as measured by ICW.
(A, B) SVG-A cells were mock infected (cMEM without virus) or infected with JCPyV (MOI = 0.5 FFU/cell) for the
specified duration and were then fixed and subsequently stained using antibodies targeting pERK1/2 and CellTag
(to normalize to the total number of cells). (B) The percentage of pERK at each timepoint was quantitated by ICW
signal intensity values per [(pERK/Cell Tag) x 100%]. Data from nine samples are represented by box and whisker
plot depicting the median and first and third quartiles. Dots represent individual points comprising box and
whisker plots. Whiskers represent values 1.5 times the distance between the first and third quartiles (inter-quartile
range). *, P < 0.05 comparing JCPyV- to mock-infected samples at specified time points. Data are representative of
three independent experiments.
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Figure 4.6. ICW characterization of SV40 polyomavirus.
SVG-A cells were infected with SV40 at indicated MOIs for 72 h. Cells were then fixed and stained for VP1
expression. SV40 VP1 expression was analyzed by ICW and FFU quantitation as in Figure 1. (A) ICW plates were
stained with CellTag 700 (red) and a LI-COR-800 secondary antibody to target VP1 (green). (B) For each
experimental assay, a minimum of triplicate samples were analyzed and the percent infection or percent response
for each treatment was normalized to the DMSO control, which was set to 100%. For each experimental assay, the
percent infection or percent response of a given MOI was normalized to the highest MOI, which was set to 100%.
Error bars are representative of the standard deviation from the mean. (C) ICW and FFU data were compared
across identical conditions by linear regression and an experimental correlation was determined using a Pearson
correlation coefficient. The grey shaded region represents the confidence interval (standard error of the linear
regression). Error bars represent the standard deviation from the mean. *, P < 0.05. Data are representative of
three independent experiments.

4.5. Discussion

The study of viral infections in vitro has provided innumerable advances to the field of virology.
However, the lack of rapid and efficient screening tools has hindered research progress for some viruses,
like JCPyV [23,319]. To overcome this challenge, the development of high-throughput analyses is needed
to help aid in the production of large data sets and generation of multiple lines of inquiry. Current
methodologies for analyzing JCPyV infectivity predominantly rely on manual quantitation of infection by
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indirect immunodetection of viral proteins by epifluorescence microscopy. While these methodologies
have provided crucial information into the characterization of JCPyV infectivity, the low throughput
nature of microscopy-based techniques has prevented the employment of large-scale screens and also
hindered productivity within the field. Adapting the ICW procedure to effectively measure JCPyV
infectivity has enabled faster analysis by improving efficiency by ~9 person hours per 96-well plate in
comparison to traditional FFU manual assessments. Moreover, this semi-automated assay allows for
enhanced user objectivity. Utilization of ICW analysis to detect JCPyV infection and viral impacts on hostcell proteins provides a new technological platform for large scale screens to measure the viral response
to treatments such as inhibitors or siRNAs with enhanced efficiency and reduced use of resources.

The results described herein demonstrate that the ICW provides a rapid, robust, and accurate
measure of infectivity and can also assess viral impacts on host-cell protein expression. Previous work
has shown that the ICW can be utilized for quantifying viral infectivity of multiple types of viruses,
including influenza, herpes simplex virus, reovirus, and rotavirus [324-326]. To confirm that the ICW can
be used to measure JCPyV infectivity with accuracy, SVG-A cells were subjected to JCPyV infection at
varying MOIs for both FFU and ICW quantitation (Figure 4.2). Both assays demonstrated increasing
detection of VP1 with increasing MOIs, demonstrating a positive Pearson correlation coefficient (Figure
4.2). The positive correlation between the traditional microscopic quantitation of JCPyV and the ICW
approach indicates that the ICW is a reliable and accurate technique to characterize JCPyV infectivity.
However, a limitation of the ICW includes the quantifiable limit of viral protein expression, particularly
when administering low viral MOIs for infectivity assessment. For most JCPyV-associated experiments,
using a MOI of 0.1 FFU/cell and greater produced more representative and reproducible results,
suggesting that this may be the lower limit of detection for this assay when assessing JCPyV infectivity
by VP1 expression. Together these findings confirm that the ICW can be utilized to quantitate JCPyV
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infection in SVG-A cells (Figure 4.2) and as such, JCPyV infectivity can be accurately quantitated using
this novel methodology.

Due to viral dependency on the host cell for infectivity, virus-host cell interactions are a key area
of focus in virology research. To explore whether viral inhibition can be measured by ICW during JCPyV
infection, SVG-A cells were exposed to chemical inhibitors targeting endocytic pathways and the MAPK
cascade. Under all treatments, as measured by both FFU and ICW, JCPyV infectivity was significantly
reduced in comparison to controls (Figure 4.3) suggesting that ICW is a viable option for screening
potential anti-viral compounds. Moreover, JCPyV infectivity can be scored in response to siRNA
knockdown of proteins known to significantly decrease infection [132], as VP1 expression was
significantly decreased in cells lacking ERK1/2 as measured by both FFU and ICW (Figure 4.4).
Importantly, these findings demonstrate that the ICW is capable of detecting changes in JCPyV
infectivity following siRNA inhibition supporting its use in conjunction with high-throughput drug and
siRNA screening libraries.

JCPyV has been previously shown to upregulate the critical MAPK signaling molecule ERK early in
the infectious process to facilitate viral infection [46,132]. Through the ICW, alterations to normal
expression or activation of ERK and other proteins can be quantitated in this plate-based system faster
and more reproducibly to alternative traditional western blotting methods [336,337]. While this
technique has been previously used to detect phosphoproteins, it has had limited adaptations with
virology-based studies. We have adapted this sensitive and quantitative measure of protein
phosphorylation to assess viral impact on host-protein expression. Quantitation of pERK by ICW
demonstrated that JCPyV-induced activation of ERK was robust at early timepoints during infection
(Figure 4.5), in line with previously published results [132], suggesting that the ICW can accurately
detect host-cell protein changes during viral infection. The ICW provides an advantage over traditional
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western-blot techniques as cells can be fixed under more controlled intervals and processed directly
within the sample plate. These findings highlight the capacity of this assay to analyze changes in hostcell protein response due to viral infection, suggesting it can be successfully applied to large-scale
studies of viral-induced proteomic alterations.

In addition, the ICW can also be adapted to measure infectivity of other polyomaviruses like
SV40 PyV [335]. SVG-A cells infected with SV40 quantified by both FFU and ICW demonstrated a
corresponding increase in both percent infection and percent response with increasing MOIs, which
proved to be positively correlated (Figure 4.6). These findings indicate that SV40 infection may also be
characterized by the ICW assay and suggest that this assay could be adapted for the detection of other
polyomaviruses such as BK polyomavirus. Thus, this assay can be further validated and developed for
other viruses and cell types. Together these results demonstrate the dynamic range of experimental
designs that can be investigated using the ICW. With a rapid and automated approach, a significant
amount of experimental information can be generated under high-throughput conditions and analyzed
quickly and efficiently with this novel technology.

The ICW assay was initially designed to study protein expression in lieu of the traditional western
blot system [337]. This system captures information regarding proteins of interest in a context that is
directly pertinent to the cell, in a matter of hours rather than days. Since its implementation, it has been
adapted to study viral protein production during the infectious process and characterize viral infection
under different experimental conditions. This high-throughput application provides the means by which
researchers can generate large data sets that can help drive productive research forward in a quick,
unbiased manner, which can now be applied to the study of JCPyV. The addition of this new technology
for characterizing JCPyV provides an advance to the field as the current methods for detection are
limited to microscopy-based FFU assays, as JCPyV can neither be measured via plaque assay, nor studied
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in small animal model systems [336,337]. Thus, the findings described herein demonstrate that the ICW
provides a unique high-throughput platform for quantifying viral infectivity that can be utilized to
increase the rate of discovery and drive the study of Polyomaviridae forward.
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CHAPTER 5
FUTURE DIRECTIONS AND CONCLUDING REMARKS
My thesis research has elucidated the role of the MAPK-ERK signaling mechanism in JCPyV
infection, the key regulator of JCPyV gene transcription. Through the activation of this key
communication pathway, JCPyV, like other DNA viruses, can manipulate multiple facets of the host-cell
in order to reprogram it into a virus-producing factory. The requirement of the MAPK-ERK proteins Raf,
MEK, and ERK in JCPyV infection highlight viral reliance on not only the functionality of this particular
pathway, but the necessity with which viruses must reprogram signaling cascades in order to
successfully infect the host-cell. Interestingly, the consequences of JCPyV activation of the MAPK-ERK
pathway is seemingly two-fold. As activation of the terminal kinase ERK, demonstrates a multiphasic
patterning of activation over the course of infection, this pathway may be facilitating not only particular
steps in the virus lifecycle, but also may be driving the cell into a proliferative state or even preventing
apoptosis. Moreover, the activation of downstream transcription factors linked to the MAPK-ERK
pathway suggests JCPyV reliance on the MAPK-ERK pathway to redirect and reprogram the prototypical
functionalities of these transcription factors towards viral replication and eventual survival.
While these works have highlighted the importance of the key components of the MAPK-ERK
cascade in JCPyV infection, currently little is known regarding the direct mechanism of MAPK-ERK
activation utilized by the virus. Recent reports have identified a direct but transient interaction of JCPyV
virions with the 5-HT2Rs at times congruent with viral internalization [43]. These serotonin receptors act
as key proteins involved in the transmission of neurotransmitter signals, the activation of which has
been definitively linked to the activation of the MAPK-ERK cascade [131]. Due to the overwhelming
complexity of the MAPK-ERK pathway, it is difficult to isolate the direct mode of activation of this
pathway upon JCPyV infection, however there are some potential lines of inquiry that bear further
investigation.
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The interplay between virus and host is an exceedingly complex and strategic battle, the
consequences of which can have long-lasting and broad implications in the host. A successful viral
infection is predicated on viral manipulation and reprogramming of key host-cell proteins that will
facilitate replication of the viral genome. As a master regulator of key processes within the cell, the
MAPK-ERK cascade plays a critical role in promoting gene expression, activating pro-survival
mechanisms, inducing host-cell immune mediators, and regulating the cell cycle [71]. By hijacking the
MAPK-ERK pathway, viruses have near unlimited control over the fate of the cell, allowing viruses to
manipulate cells for viral replication.
Interestingly, protein kinases now represent one of the largest group of cellular targets in
pharmaceutical drug development, particularly in newly synthesized oncology drugs [338]. Since the first
kinase inhibitor was approved by the FDA in 2001, over 25 different small molecule kinase inhibitors
have been approved for use [339]. The Raf inhibitors vemurafenib [340] and sorafenib [341] and MEK
inhibitors trametinib [342] and selumetinib [343] represent efforts of drug discovery teams to highlight
the clinical importance of protein kinases not only in the single-cell environment, but to improve human
health. These kinase inhibitors, originally developed to treat multiple types of human cancers including
metastatic melanomas [339], as well as renal and hepatocellular carcinomas [344,345], signify an
intriguing opportunity for virology researchers and clinicians to explore the impacts of these FDAapproved MAPK inhibitors on DNA virus infection. In particular, the use of current kinase inhibitors or
development of novel antiviral drugs for JCPyV is of particular importance given the fatality and poor
prognosis with PML. Fortunately, analysis of FDA-approved drug libraries or siRNA screens to identify
potential anti-viral therapeutics for treating JCPyV infection are now more feasible with the advent of
the novel ICW technology that we have developed and described herein.
The complexity of biological signaling networks cannot be overstated, even in a canonical
setting. These pathways are the interpreters of the cellular environment; one pathway can transmit
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many different signals, or one stimulus could be transmitted by many different pathways. In the cases of
virus dysregulation of signaling pathways, these potentially redundant functions allow for multiple
opportunities for successful infection. Further insight into the complexity of signaling pathway
communication is required not only to gain a better understanding the cell itself, but to clarify avenues
that may be exploited by viruses and other pathogens.
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